

**Harvard Medical School
Curriculum Vitae**

Date Prepared: 10/15/2021

Name: Merit Ester Cudkowicz

Office Address: Massachusetts General Hospital
55 Fruit Street, WACC 720
Boston, MA 02114

Home Address: 34 Winchester Plaza
Newton, MA 02461

Work Phone: (617) 726-2383

Work Email: Cudkowicz.Merit@mgh.harvard.edu

Work FAX: (617) 726-2353

Place of Birth: Oak Ridge, Tennessee

Education

1985	B.S. Tau Beta Pi	Chemical Engineering	Massachusetts Institute of Technology
1990	M.D.	Medicine	Harvard Medical School, Harvard- Massachusetts Institute of Technology. Division of Health, Science and Technology
1996	MSc.	Clinical Epidemiology	Harvard School of Public Health

Post Graduate Courses

2010-2012	Physician Leadership Development Certificate Program	Massachusetts General Hospital
2013	Program for Chiefs of Clinical Service	Harvard School of Public Health

Postdoctoral Training

07/90-6/91	Intern	Medicine	Beth Israel Hospital
07/91-6/93	Resident	Neurology	Massachusetts General Hospital
07/93-6/94	Chief Resident	Neurology	Massachusetts General Hospital
07/94-6/96	Clinical Research Fellow	Neurology	Clinical Investigator Training Program, Harvard/M.I.T. Health Sciences and

Technology-Beth Israel Hospital in collaboration with Pfizer

Faculty Academic Appointments

07/95-6/97	Instructor	Neurology	Harvard Medical School
07/97-6/02	Assistant Professor	Neurology	Harvard Medical School
07/02-12/09	Associate Professor	Neurology	Harvard Medical School
01/10-	Julianne Dorn Professor	Neurology	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

Past

06/96-4/03	Assistant in Neurology	Neurology	Massachusetts General Hospital
1996-1997	Research Affiliate	General Clinical Research Center	Massachusetts Institute of Technology
2004-2006	Staff Researcher	Neurology	Edith Norse Bedford Veteran's Administration Hospital
1998-	Associate in Neurology	Neurology	Brigham and Women's Hospital
04/03-4/11	Associate in Neurology	Neurology	Massachusetts General Hospital

Current

04/11-	Neurologist	Neurology	Massachusetts General Hospital
05/12-	Chief, Neurology Service	Neurology	Massachusetts General Hospital
06/20-	Clinical Consultant	Neurology	Brigham and Women's Hospital

Other Professional Positions

2000-2001	Medical Advisory Board	Medtronic
2004	ALS Advisory Board	Jazz Pharmaceutical
2005-2007	Scientific Advisory Board	Teva Pharmaceuticals
2008-2009	Medical Advisory Board	Acceleron
2007-2008	Scientific Advisory Board	Clinical Research Network for Friedrich's Ataxia
2008	Scientific Advisory Board	Ruxton
2009	Scientific Advisory Board	Roche
2009-2011	Scientific Advisory Board	GlaxoSmithKline
2008	Scientific Advisory Board	Ruxton
2012	Scientific Advisory Board	Coyote Pharmaceuticals
2012-2015	Scientific Advisory Board	DART
2016	ALS Endpoint Advisory Board	Biogen
2018	Executive Advisory Committee	P01 SAB

2019-	Science Advisory Board	Pathophysiology of genetically: Defined Dementia and
2020-	Science Advisory Board	Neurodegeneration: Defining Therapeutic Targets and Pathways
2020-	Science Advisory Board	ALS Therapy Development Fund NeuroSence BioTrust

Major Administrative Leadership Positions

Local

1997-2019	Co-Director, Neurology Clinical Research Institute (NCRI)	Massachusetts General Hospital
1998-2008	Co-Director, Amyotrophic Lateral Sclerosis (ALS) Center	Massachusetts General Hospital
2001-2006	Co-Director, Harvard Center for Neurodegeneration and Repair, Core A Neurologic Clinical Trial Service	Harvard Medical School
2007-2008	Co-Director, Muscular Dystrophy Association Neuromuscular clinic	Massachusetts General Hospital
2008-2016	Director, Muscular Dystrophy Association Neuromuscular clinic	Massachusetts General Hospital
2009-2016	Division Co-Chief, Neuromuscular	Massachusetts General Hospital
2012-2013	Chair, Research Strategy Team Clinical Research	Massachusetts General Hospital
2018-2021	Vice Chair, ECOR	Massachusetts General Hospital
2018	Director, Healey Center for ALS	Massachusetts General Hospital
2019	Chair, Search Committee for Psychiatry	Massachusetts General Hospital
2021-2024	Chair, ECOR	Massachusetts General Hospital
2021	Chair, Search Committee for Director Division Clinical Research	Massachusetts General Hospital

National

2007-2012	Co-Director, Clinical Trial Methods Course	National Institute of Neurological Disorders and Stroke
2007	Co-Chair and Organizer, Banbury ALS Drug Discovery Workshop	ALS Association
2007	Course Director, Selecting Experimental treatments for clinical testing	Huntington's Disease Study Group
2009	Chair and Organizer, ALS Phase 2 Design Workshop	Muscular Dystrophy Association
2014-2021	Chief Medical Officer	ALS Finding A Cure Foundation

International

2008	Co-Director, Biomarkers in ALS Symposium, Birmingham, UK	World Federation of Neurology
------	--	-------------------------------

2010	Chair, International Motor Neuron Disease Symposium	Motor Neuron Disease Association
2011	Session Chair, ICSCN Workshop	Motor Neuron Disease Association

Committee Service

Local

1993	Neurology resident selection committee	Massachusetts General Hospital Member
1996-2004	Scientific Advisory Board	General Clinical Research Center, Massachusetts General Hospital Member
1996-1997	Clinical Research Education Unit, Clinical Research Program	Massachusetts General Hospital Member
1999-2007	Clinical Research Council	Massachusetts General Hospital Member
2001-2002	Center of Excellence in Women's Health Committee	Harvard Medical School Member
2001-2004	Admissions Committee	Health Science and Technology Medical School Member
2004-2008	Neurology Department Finance Committee	Massachusetts General Hospital Member
2005-2007	Neurology Department Leadership Committee	Massachusetts General Hospital Member
2006-2007	Women's Health Research Committee	Massachusetts General Hospital Member
2006-2007	Search Committee Sleep Unit Co-Director	Massachusetts General Hospital Member
2007-2010	Clinical Research Steering Committee	Massachusetts General Hospital Member
2007-2010	Neurology Clinical Operations Committee	Massachusetts General Hospital Member
2007-2012	Neurology Research Operations Committee	Massachusetts General Hospital Member
2008-2012	Neurology Clinic Directors Committee	Massachusetts General Hospital Member
2009-2011	Research Compliance Committee	Massachusetts General Hospital Member
2009-	Catalyst Participant and Clinical Interactions Resource Scientific and Resource Review Committee	Harvard Medical School Member
2011	Standing Committee on Conflicts of Interest	Harvard Medical School Member
2011	Harvard Catalyst KL2 Admissions Committee	Harvard Catalyst Member
2011	Committee for appointment of Dr. Christopher P. Cannon as Professor of Medicine	Harvard Medical School Member, Brigham and Women's Hospital

2012-	Massachusetts General Physicians Organization Executive Committee	Massachusetts General Hospital Member
2012	Committee for Professor appointment of Dr. Ronald J. Anderson as Professor of Medicine	Harvard Medical School Member
2012-2013	Ad hoc committee search for Chief of the Department of Otolaryngology	Harvard Medical School Massachusetts General Hospital
2012-	Executive Committee on Research	Massachusetts General Hospital Member
2013-2014	Research and Licensing Commercialization Council	Partners Healthcare Member
2016	Ad hoc committee search for Chief of the Department of Neurosurgery	Harvard Medical School Massachusetts General Hospital
2017	2017 World Neuroscience Springboard Committee	Partners Healthcare Member

National and International

1996-	Executive Committee	Northeast ALS Consortium
	1996-2015	Co-Chair and Founder
	2016-	Member
1997-2004	Executive Board	ALS Care Member
1999-2001	Steering Committee Riluzole in Huntington's Disease	Huntington Study Group Co-Chair
2000-2003	Steering Committee Minocycline in Huntington's Disease	Huntington Study Group Chair
2000-2018	Muscular Dystrophy Association Research Advisory Committee	Member
2001-2003	Safety Monitoring Committee Creatine in Huntington's Disease	Huntington Study Group Chair
2003-2005	Steering Committee Clinical trial of TCH386	Novartis Member
2005-2008	Data Safety Monitoring Committee Somatokine in Myotonic Dystrophy	National Institute of Neurological Disorders and Stroke (NINDS) Member
2005-	Executive Committee	ALS Research Group
	2007-08	Vice Chair
	2009-11	Chair
2005-2007	Steering Committee Arimoclomol in ALS	Cytrx Inc. Chair
2005-2013	Steering Committee Ceftriaxone in ALS	NINDS Chair
2005-2008	Steering Committee Minocycline in Huntington's Disease II	Huntington Study Group Chair
2005-2006	Data Safety Monitoring Board	NIH Rare Diseases Clinical Research Network, Member
2006	Steering Committee	Mediation

2006	DIMOND Huntington Disease Trial Steering Committee	Member NINDS
	PREQUEL: CoQ for presymptomatic Huntington's Disease	Member
2007-2008	Data Safety Monitoring Board	Ono Pharmaceuticals Member
2007-2010	Data Safety Monitoring Board	Synapse Biomedical Chair
2007-2008	Advisory Panel for Clinical Research	NINDS Co-Chair
2008-2011	Steering Committee	Michael J Fox Foundation for Parkinson's Research (Foundation)
2008-2009	Inosine in Parkinson's Disease ALS Translational Research Advisory Committee	Muscular Dystrophy Association Member
2008-2010	Steering Committee	Knopp Neurosciences Inc
	KNS760704 in ALS	Chair
2009-2011	Data Safety Monitoring Board	Trophos Chair
2009-2015	Sheila Essey Award: An Award for ALS Research Workgroup	Workgroup Member
2010	Therapy Development Committee for Spinal Muscular Atrophy	NINDS Member
2011	Organizing Committee Tarrytown II ALS Conference to promote clinical research to find the cure for ALS.	NINDS
2011	FDA Mock Advisory Panel	Millenium
2014-2018	Data Safety Monitoring Board	Lilly Pharmaceuticals Chair
2015-	Executive Committee	Cytokinetics
	Tirasemtiv Phase III Trials in ALS	Member
2015-2019	Steering Committee	ALSA/ALSFAC/GSK
	Retigabine in ALS	Member
2015-	Steering Committee	Biogen
	ALS SOD1 Phase 1 233AS101	Member
2015-	Publication Committee	Cytokinetics Member
2016-	Peripheral and Central Nervous System Drugs Advisory Committee	FDA Member
2016-2022	Advisory Council for the Brown Institute for Brain Science (BIBS)	Brown University
	2016-2019	Member
	2019-2022	Permanent Member
2016-	ALS Scientific Communication & Education External Expert Steering Committee	Mitsubishi Tanabe Pharma/MTPA Chair
2016-2020	Steering Committee	Amylyx
	AMX0035 for ALS	Member
2016-2020	Steering Committee	NINDS
	Sure PD-3 Clinical Trial	Member
2017	ALS Advisory Board	Biogen

2017	C9orf72 ASO Phase 1 Study Scientific Education and Communication Steering Committee	Member MT Pharma Chair
2018-	Neurobiology Sub-Committee Quarterly Sub-Committee Meeting	Warren Alpert Foundation Chair
2020	Steering Committee Member,	AB Sciences
2019-	Intramural Review Committee, Member	NINDS
2021	The EU Academy of Sciences (EUAS)	Member
2020-2024	Committee for The Board of Scientific Counselors for NINDS 7/6/2020-6/30/2024	Member
2021-	Association of American Physicians	Councilor
2022	American Brain Foundation	Board Member

Professional Societies

1983-	Sigma Xi Research Society	Member
1983-	Tau Beta Pi National Engineering Honor Society	Member
1990-	American Academy of Neurology	
	2001-2008	Abstract Reviewer
	2005-2008	Chair, Anterior Horn Topic
	2005-2009	Member, Clinical Research
	2009-2011	Subcommittee
	2009-2011	Chair, Clinical Research Subcommittee
	2009-2011	Member, Science Committee
		Member, Translational Neuroscience
	2009-2013	Subcommittee
	2009-2013	Chair, AAN Foundation Research Council
	2009	Member, Sheila Essey Award Subcommittee
	2011-2012	Member, Presidential task force on NIH
	2013	Multi-institutional Collaborations Chair, Fellowship Workforce
		AAN Foundation Research Council
	2015-	ABF Research Advisory Committee Member
1994-	Huntington Study Group	Member
1998-2003	Society for Neuroscience	Member
2001-	World Federation of Neurology	
	2006-2010	Member, Motor Neuron Disease Executive Committee
2001-2015	The Amyotrophic Lateral Sclerosis Association (ALSA)	Member, Massachusetts Chapter Scientific Advisory Board
	2001-2002	Neuroepidemiology consultant
2005-	The American Neurological Association	

	2005-2007 2006-2009	Member, Scientific Program Committee Member, Clinical Trial Summer Course Committee
	2007-2009 2013	Member, Long Range Planning Committee Member, Scientific Program Advisory Committee
2009-	The American Society of Experimental NeuroTherapeutics (ASENT)	
	2009- 2010-2018	Member Editorial Board of <i>NeuroTherapeutics</i>
2011	American Federation for Medical Research	Member
2016	American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)	Honorary Member

Grant Review Activities

2000-2018	Medical Advisory Committee Review Panel	Muscular Dystrophy Association Permanent Member
2009-2013	Venture Philanthropy Advisory Grant Review Board	Muscular Dystrophy Association Member
2002	NINDS Special Emphasis Panel	National Institutes of Health Ad hoc Member
2002-2003	NSD-K Clinical Trial Review Panel	National Institutes of Health Ad hoc Member
2003	Peer Reviewed Medical Research Program	Department of Defense Reviewer
2003-2008	Scientific Review Committee	The Amyotrophic Lateral Sclerosis Association Member
2005-2011	AAN Clinical Fellowship Review Committee	American Academy of Neurology
	2005-2009 2009-2011	Member Chair
2006-2008	Scientific Review Committee	Les Turner ALS Foundation Member
2007	Scientific Review Committee	Spastic Paraplegia Foundation Member
2009-2010	Scientific Review Committee	AriSLA Foundation of Italy Reviewer
2009-2010	ALS Research Program Integration	Department of Defense Reviewer
2010-2011	Myopathies Scientific Council	Association Francaise Reviewer
2010	Brain Bank Review Committee	Veteran's Affairs Reviewer
2011	Scientific Review Committee Advisory Board	Thierry Latran Reviewer

2013-	Independent Review Committee TARGET ALS	Columbia University/P2ALS Review Board Member
2014-	Scientific Review Committee	Weston Institute Reviewer
2016-	Scientific Review Committee	Joint FTD and AD Drug Foundation Reviewer/Member

Editorial Activities

Ad hoc Reviewer

Annals of Neurology
Brain
Journal of Neurology and Neuropsychiatry
Lancet Neurology
Muscle and Nerve
Neurology
Neuroscience
New England Journal of Medicine

Other Editorial Roles

2008-	Editorial Board Member	ALS Journal
2009-2010	Editorial Board Member	Neurological Bulletins
2010-2018	Editorial Board Member	ASENT <i>NeuroTherapeutics</i>
2011	Editorial Board Member	Journal of Huntington's Disease
2012-	Editorial Board Member	JAMA Neurology
2012	Editorial Board Member	Cureus.com
2013	Editorial Board Member	Annals of Clinical and Translational

Honors and Prizes

2003	Angel Fund Award in ALS Research	
2006	Wings Over Wall Street MDA ALS Research Award	
2009	Sheila Essey AAN ALS Research Award	American Academy of Neurology
2012	Prize4Life Pioneer Award Leonard Gerson	
2013	Distinguished Scholar Award	University of Pittsburgh
2015	Joseph B. Martin Dean's Leadership Award Advancement of Women Faculty	Harvard Medical School
2015	Partners in Excellence Award	Massachusetts General Hospital
2017	Honorary Membership in American Association of	AANEM

	Neuromuscular & Electrodiagnostic Medicine	
2017	Forbes Norris Award	International Alliance of MND
2018	Pinnacle Award	Boston Chamber of Commerce
2019	Nominated for Membership	Association of American Physicians
2019	Raymond D. Adams Lectureship Award	American Neurological Association
2020	Diamond Award Honoree	Muscular Dystrophy Association Wings Over Wall Street Committee
2020	One of the top 10 people Transforming Healthcare	Business Insider
2020	Election to membership in the National Academy of Medicine	National Academy of Medicine
2021	Top 10 Clinical Research Achievement Award Centaur Trial for ALS Study	Institute for Clinical Research and Translational Science Institute Tufts Medical Center
2021	Election to Membership to The EU Academy of Sciences (EUAS)	Member
2021	Pillars of Excellence Award	Mass General Brigham
2021	Merit of Distinction Award For abstract "Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS"	American Academy of Neurology and The Science Committee
2021	Brian A. McGovern, MD Award for Clinical Excellence	Nominated for Massachusetts General Physicians Organization

Report of Funded and Unfunded Projects

Funding Information

Past

- 1994-1996 **Therapeutic Trial of Free Radical Scavengers in Amyotrophic lateral sclerosis**
Pharmaceutical Manufacturer's Association Clinical Pharmacology Fellowship
PI (Fellow)
The major goal of this investigator led study was to determine safety, pharmacokinetics and efficacy of procysteine in people with amyotrophic lateral sclerosis.
- 1994-1996 **Clinical Investigators Training Program Fellowship, Harvard/M.I.T. Health Sciences and Technology** - Beth Israel Hospital, in collaboration with Pfizer
PI (Fellow)
- 1996-1998 **Genetic Epidemiology and Therapeutic Strategies in ALS**
American Academy of Neurology Education and Research Foundation
Clinical Research Training Fellowship (First awardee)
PI (\$70,000)
The major goal of the study was to determine risk and prognostic factors for ALS.

- 1996-2001 **Risk Factors and Therapeutic Strategies in ALS**
 NINDS K08 NS001896
 PI (\$443,458)
 This was a mentored training grant to study risk factors for ALS and to test novel treatments in people with ALS.
- 1997-1999 **Pathogenesis of ALS in SOD-1 Transgenic Mice**
 The Amyotrophic Lateral Sclerosis Association (Foundation)
 PI (\$18,004)
 The major goal of the study was to determine whether approaches to decrease oxidative toxicity were effective in an animal model of ALS.
- 1997-1999 **Pathogenesis of ALS in SOD-1 Transgenic Mice**
 Muscular Dystrophy Association (Foundation)
 PI (\$144,397)
 The major goal of the study was to determine whether approaches to decrease oxidative toxicity were effective in an animal model of ALS (supplementary).
- 1997-2001 **Remacemide and Coenzyme Q₁₀ Therapy in Huntington's Disease**
 National Institute of Health NINDS R01 NS35284
 Site PI (\$90,575)
 This was an investigator led 2X2 factorial design clinical trial of remacemide and coenzyme Q10 in over 300 patients with Huntington's disease.
- 1998-2000 **Determinants of disease severity in ALS**
 Massachusetts General Hospital Claflin Award
 PI
 The study goal was to determine clinical and biological factors that affect prognosis in ALS.
- 1998-2000 **Clinical trial of intrathecal BDNF in ALS**
 Amgen (Industry)
 Site PI (\$405,229)
 The study goal was to determine the long term safety and efficacy of BDNF in ALS.
- 1998-2001 **Pathogenesis of ALS in SOD-1 Transgenic Mice (Brown, R)**
 NINDS R01 NS36640
 Co-PI (\$245,662)
 The major goal of the study was to determine whether approaches to decrease oxidative toxicity were effective in an animal model of ALS.
- 1998-2001 **Studies of ALS genes and analysis of genes and candidate therapies in ALS (Brown, R)**
 The Amyotrophic Lateral Sclerosis Association (Foundation)
 Co-PI (\$100,000)
 To find new ALS genes.
- 1999-2001 **Clinical trial of subcutaneous brain derived neurotrophic factor (BDNF) in ALS**
 Regeneron (Industry)
 Site PI (\$95,919)
 This was a phase 3 clinical trial of BDNF in people with ALS.
- 1999-2001 **Riluzole Dosing in Huntington's Disease (Marshall, F)**
 Orphan Products Development Office, FDA
 Co-PI
 This was an academic led phase 2 safety and dose finding study of Riluzole in people with Huntington's disease.
- 1999-2002 **Clinical trial of Topiramate in ALS**

- Ortho-McNeil Pharmaceutical (Industry)
Study PI– Investigator initiated Clinical Trial (\$248,704)
MGH Neurology Clinical Trials Unit – Coordination and Data Management Center
This was an academic led multi-center phase 2/3 clinical trial of Topiramate in ALS.
- 1999-2002 **Clinical trial of Topiramate in ALS**
Muscular Dystrophy Association (Foundation)
PI (\$98,781)
To test Efficiency and safety of Topiramate in ALS.
- 1999-2003 **Creatine therapy in ALS** (Shefner, J)
Avicena & Muscular Dystrophy Association (Foundation)
Co-PI (\$34,606)
This was an academic led, multi-center phase 2 clinical trial of Creatine in ALS.
Avicena supplied study drug and supplementary funding.
- 1999-2003 **Clinical Trial of Creatine in ALS**
MDA/Johns Hopkins University Subcontract
PI (\$54,799)
This was an academic led, multi-center phase 2 clinical trial of Creatine in ALS. Funding was obtained from MDA and Avicena.
- 2000-2001 **Open-label remacemide clinical study in Huntington’s Disease**
Astra Pharmaceuticals (Industry)
Site PI (\$95,400)
Clinical trial of remacemide in Huntington’s Disease
- 2000-2004 **Clinical trial of Topiramate in ALS**
National Institute of Health NINDS R01 NS39988
Pilot Clinical Trial Grant
PI (\$1,073,193)
This was an investigator initiated clinical trial (20 sites) of Topiramate in people with ALS.
- 2001 **Treatment of transgenic ALS mice with a novel cytokine** (Brown, R)
Biogen (Industry)
Co-PI (\$72,262)
Develop treatments for ALS.
- 2001-2002 **Dextromethorphan/quinidine treatment for pseudobulbar affect in ALS**
Avanir Pharmaceuticals (Industry)
Site PI (\$29,470)
The study goal was to determine the symptomatic effects of dextromethorphan/quinidine on pseudobulbar affect in patients with ALS.
- 2001-2002 **Treatment of ALS mice with ONO-2506** (Brown, R).
Ono Pharmaceuticals (Industry)
Co-PI (\$49,712)
The study goal was to determine efficacy of ONO-2506 in a mouse model of ALS.
- 2001-2003 **Clinical trial of Minocycline in HD**
Orphan Product Development Grant, FDA FDR-001968
PI (\$592,188)
This was a phase 2 investigator initiated clinical trial (8 sites) of Minocycline in 60 people with Huntington’s disease.
- 2001-2004 **Clinical Trial of Celebrex in Subjects with ALS** (Drachman, D).
Muscular Dystrophy Association (Foundation)
Co-PI (\$158,680)

- The study was an investigator initiated phase 2/3 clinical trial (25 sites) of Celebrex in 300 people with ALS (supplementary).
- 2001-2005 **HCNR Core A Clinical Research**
Harvard Medical School
PI (\$706,450)
Funds were provided to build clinical research infrastructure at Partners.
- 2002-2004 **P35 caspase inhibition in an ALS mouse model**
Muscular Dystrophy Association (Foundation)
PI (\$116,073)
Develop treatment for ALS.
- 2003-2004 **Pilot Safety and Tolerability Study of Coenzyme Q10 in Huntington's Disease and Normal Subjects**
University of Rochester Subcontract
Co-PI (\$35,300)
This was an academic led phase 2 study to determine the maximum tolerated dosage of Coenzyme Q10 in preparation for a subsequent phase 3 efficacy study.
- 2003-2005 **Clinical trial of TCH386 in ALS**
Novartis (Industry)
Site PI and Steering Committee Member (\$119,906)
The study was a phase 2 clinical trial of four dosage of TCH386 in 500 people with ALS.
- 2004-2006 **Metabolomics in ALS**
NIEHS/R21 ES013470
PI (\$280,506)
The main goal was to study the metabolomic profile in blood and cerebrospinal fluid from people with ALS to better understand disease pathways and targets.
- 2004-2006 **Identification of Diagnostic Biomarkers and Therapeutic Targets for ALS**
ALS Association
PI (\$45,000)
The main goal was to study the metabolomic profile in blood and cerebrospinal fluid from people with ALS to better understand disease pathways and targets.
- 2004-2007 **Metabolomics and proteomics in ALS**
The Amyotrophic Lateral Sclerosis Association (Foundation)
PI (160,000)
The study goal was to build a biobank of well characterized samples and clinical data from people with ALS and controls for biomarker studies.
- 2004-2007 **Safety and tolerability study of sodium phenylbutrate in ALS**
VA Grant, Bedford VA
CoPI (PI Ferrante)
- 2004-2014 **Clinical Trial of Ceftriaxone in Patients with ALS**
NINDS U01 NS049640
Overall Study PI (\$32,737,110)
This is an academic led, adaptive design phase 1-3 investigator initiated clinical trial (62 sites) to determine the safety, dosage and efficacy of Ceftriaxone in people with ALS. MGH is the Coordination and Data management center for this trial.
- 2005-2006 **Safety and tolerability study of sodium phenylbutrate in ALS**
Muscular Dystrophy Association (Foundation)
PI (\$140,417)
The MDA provided supplementary funds to cover laboratory costs for this phase 2 academic led clinical trial.

- 2005-2006 **ALS Research Group DNA Banking Study**
 NINDS, Supplement NS 049640-02S1
 Co-PI (\$38,661)
 The main goal was to create a bank of DNA samples from patients with ALS for research.
- 2005-2006 **Double-Blind, Randomized, Placebo-Controlled, Phase 1 Multiple dose Study to evaluate the safety, tolerability and Pharmacokinetics of AEOL 10150 Administered by Subcutaneous Injections in Patients with ALS**
 Aeolus Pharmaceuticals, Inc
 Site PI and Steering Committee Member (\$157,766)
 This study was designed to test the safety and pharmacokinetics of multiple doses of an antioxidant, AEOL 10150. MGH was a site in this trial.
- 2005-2007 **Phase IIa clinical study of Arimoclomol in ALS**
 CytRx Corporation (Industry)
 PI (Overall PI, Coordination and Data Management Center) \$1,015,797
 This trial was a multi-center, safety, pharmacokinetic, dose finding study of Arimoclomol, an activated of heat shock factor, in people with ALS.
- 2005-2007 **Clinical Trial of High Dose Coenzyme Q10 in ALS**
 NINDS/Columbia University Subcontract
 Co-Site Investigator (\$5,902)
 The goal of this academic led phase II was to determine whether Coenzyme Q10 was worth taking forward to a phase III trial (futility design study). MGH was a site in this study.
- 2005-2016 **Coenzyme Q10 in Huntington's Disease**
 NINDS U01 NS52592
 Overall Study PI (\$7,660,189)
 The study is an investigator initiated phase 3 clinical trial (46 sites) of 2400 mg/day of Coenzyme Q10 in 608 people with Huntington's disease.
- 2006-2007 **Quantitative strength measurement development for ALS**
 The Amyotrophic Lateral Association (Foundation)
 PI (\$83,193)
 The main study goal was to build a new apparatus to quantitatively measure strength in People with neuromuscular disorders.
- 2006-2008 **ALS Research Group DNA Banking Study**
 Muscular Dystrophy Association (Foundation)
 Co-PI (\$91,826)
 The study goal was to gather DNA and clinical data from large numbers of patients with ALS for a national sample bank.
- 2006-2008 **Validation of ALS Metabolomic Biomarkers and Development of ALS Diagnostic**
 The Amyotrophic Lateral Association (Foundation)
 PI
 The main goal of this study was to develop a biomarker for ALS building on results from Our prior metabolomic studies. This was a collaborative project with Metabolon, Inc.
- 2006-2011 **Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) Data Management Core**
 NINDS, P50 NS051343
 Co-PI, Biostatistics and Data Management Core (\$485,797)
 The main goal is to provide data management support for all funded SPOTRIAS stroke project at MGH.

- 2006-2011 **Antisense oligonucleotide therapy for SOD1 mediated ALS**
The Amyotrophic Lateral Association (Foundation)
PI (\$300,000)
This is an investigator-initiated phase 1 gene therapy trial for patients with familial ALS caused by mutations in superoxide dismutase 1. Leadership is shared with Dr. Tim Miller at Washington University.
- 2007-2009 **Development of Huashan and Beijing Hospitals as an ALS Clinical Trial Sites**
Inter-Asia Management, Ltd. (Industry)
PI (\$38,991)
The main goal of this project was to educate and train ALS centers of excellence in care and clinical trial conduct in China.
- 2007-2010 **Validation of a new quantitative strength measurement device for ALS**
Muscular Dystrophy Association (Foundation)
PI (\$201,398)
The main study goal is to develop the prototype for new and better method to quantitate strength in ALS clinical trials.
- 2007-2010 **Predict and Prevent ALS Study**
Muscular Dystrophy Association (Foundation, Emory Subcontract)
Co-PI (\$39,908)
The study goal is to determine, using several outcome measures, the first sign of ALS in people who carry mutations in Superoxide dismutase. This data will be used to design future preventative clinical trials.
- 2007-2011 **Translational Research Grant to develop antisense oligonucleotide therapy for SOD1 mediated ALS**
Muscular Dystrophy Association/Universtiy of Washington Subcontract
Co-PI (\$190,397)
The main study goal was to complete rodent and non-rodent toxicology studies needed to support the phase 1 study in people. Support for part of the phase 1 trial included.
- 2007-2011 **Phase II trial of R-pramepexole in ALS**
Knopp Neuroscience (Industry)
Steering Committee Member, Overall PI and Site PI (\$795,700)
The main goal was to determine the safety and pharmacokinetics of three dosages of R-pramepexole in ALS. MGH is the Coordination and Data Management Center for the open label component of study.
- 2007-2011 **Metabolic Signatures in ALS**
The Amyotrophic Lateral Sclerosis Association (Foundation)
Overall PI and Coordination and Data Management Center (\$445,127)
This is a 30 center study to create a biobank with blood and cerebrospinal fluid from 600 well characterized people with ALS, disease mimics and health controls. Samples are shared with investigators studying ALS.
- 2007-2012 **Clinical Trial Methods Course**
NINDS HHSN271200700018C
Co-PI (\$62,171)
The NINDS awarded this contract to conduct a yearly training course for neurologists (fellows and junior faculty) interested in careers in clinical trial research.
- 2007-2019 **TREAT ALS NEALS Clinical Trial Network**
The Amyotrophic Lateral Sclerosis Association (Foundation)
PI (\$2,397,993)
The main goal is to provide infrastructure support to facilitate and expedite clinical trials

- Through the Northeast ALS Consortium (NEALS) (2016-2019, \$809,731)
 Specific clinical trial management support to Phase II Clinical Trial to Evaluate Safety, Tolerability, and Biomarker Engagement of AMX0035 in Patients with ALS (Study PI Paganoni, S) (2016-2019, \$854,080)
- 2008-2009 **Lithium in ALS**
 The Amyotrophic Lateral Sclerosis Association (Foundation)
 PI (\$153,662)
 This was an investigator initiated clinical trial (36 sites) to determine the efficacy of lithium in ALS.
- 2008-2009 **Coordinating Center: A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination with Riluzole in Volunteers with Amyotrophic Lateral Sclerosis (ALS)**
 National Institutes of Health NINDS U01 NS049640-04S1
 PI (\$891,845)
 This was an investigator initiated clinical trial (36 sites) to determine the efficacy of lithium in ALS.
- 2008-2009 **A Double Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy, and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients with Amyotrophic Lateral Sclerosis and Multiple Sclerosis**
 Avanir (Industry)
 Site PI (\$19,719)
 This was a pivotal, industry led phase 3 trial of a symptomatic treatment for PBA in ALS. The trial was positive and led to FDA approval.
- 2008-2010 **Trial Design Assistance Involving the use of ACE-031**
 Acceleron Pharma, Inc
 PI (up to \$16,000)
 The goal of this project was to design a Phase I and II study to test ACE-031, a drug that increases muscle bulk in people with ALS.
- 2008-2010 **A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Talampanel in Subjects with Amyotrophic Lateral Sclerosis (ALS)**
 Teva (Industry)
 Site PI (\$165,025)
 MGH was a site in this phase 3 industry led trial of talampanel, an AMPA glutamate receptor, in people with ALS.
- 2008-2012 **Coordination Center for trial of antisense oligonucleotide therapy for SOD1 mediated ALS**
 ISIS (Industry)
 PI, Coordination and Data Management Center (\$2,290,507)
 This is a joint academic and industry led phase, single dose study of a gene therapy approach for SOD1 ALS. It is the first use of an antisense oligonucleotide treatment in a neurological Disorder.
- 2008-2011 **ALS Clinical Research Network**
 Muscular Dystrophy Association (Foundation)
 PI (\$300,000)
 The MDA provides infrastructure support to five network centers, including MGH, to perform collaborative clinical research projects.
- 2008-2016 **MDA Clinic Director**

- PI (100,800/year)
The MDA provides grant support on a yearly basis for our ALS multidisciplinary clinic.
- 2009-2011 **A phase II, double blind, randomized, placebo-controlled, three-way crossover, pharmaco-kinetic and pharmacodynamic study of CK-2017357 in patients with ALS**
Cytokinetics, Inc.
Coordination Center PI, Steering Committee Member (\$459,623)
We conducted a phase 1, single dose, study of CK-2017357, a troponin skeletal muscle activator in people with ALS. MGH was the Coordination Center for the study and a site.
- 2009-2013 **Multi-Center Validation of Biomarkers for Motor Neuron Disease**
University of Pittsburgh Subcontract – ARRA Funded RC1NS068179
Co-PI; Coordination and Data Management Center (\$384,779)
The goal of this collaborative study was to collect and test cerebrospinal fluid and blood proteomic biomarkers as possible biomarkers in ALS.
- 2009-2013 **Trial of High Fat/High Calorie Diet Versus Optimal Calorie Replacement in ALS**
MDA
PI (\$450,233)
The goal of this phase 2, academic led study is to determine the safety and tolerability of high fat, high calorie diet in people with ALS who have gastrostomy tubes.
- 2009-2011 **Generation and Characterization of ALS IPS Cells**
Johns Hopkins University Subcontract – ARRA Funded RC1NS069395
Data Management PI \$25,741
This resource grant is designed to collect skin biopsies for iPS cell lines from patients with genetic mutations associated with familial ALS. Clinical data was managed by MGH.
- 2009-2017 **Phase 1 Open-Label First in Humans, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell**
Neuralstem, Inc.
Coordination and Data Management Center PI (\$964,493)
This is the first FDA approved phase 1 clinical trial of stem cells in people with ALS. MGH is the Coordination and Data Management center for this joint academic and industry led study. Surgery and cell implantation occurs at Emory.
- 2010-2016 **Specialized Program of Translational Research in Acute Stroke (SPOTRIAS)**
Data Management Core
NINDS, P50 NS051343
Co-PI, Biostatistics and Data Management Core (\$1,280,774)
The main goal is to provide data management support for all funded SPOTRIAS stroke project at MGH.
- 2011-2013 **Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS)**
Neuraltus Pharmaceuticals, Inc
PI (\$275,456)
The primary objective is to evaluate the efficacy of NP001 in subjects with ALS using the mean change in slope of ALSFRS-R.
- 2011-2014 **Clinical Research Support Agreement – EMPOWER**
Biogen IDEC, Inc
PI (\$87,136)
The goal of this project is to provide services for Biogen Idec in connection with the EMPOWER Trial.
- 2011-2015 **A Multicenter Study for the Discovery and Validation of ALS Biomarkers**

- ALS Therapy Alliance, Inc.
PI (\$1,095,961)
The aims of the proposed study are to create a biofluid repository of plasma and CSF collected from patients with amyotrophic lateral sclerosis (ALS) serially every 4-6 months for at least 2 years, and to use these longitudinal samples to explore novel biomarkers of ALS diagnosis and progression.
- 2011-2015 **Creation of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database study**
Prize4life ATA
Co-PI (\$197,119)
The primary objective is to aid creation of the pooled resource open-access ALS Clinical Trials database.
- 2011-2015 **Phase II/III Study of Arimoclomol in the Treatment of SOD1 Positive Familial Clinical**
University of Miami, R01FD003517
Co-PI (\$81,372)
The primary objective is to study the effects of Arimoclomol in the treatment of SOD1 positive.
- 2011-2016 **Trial of Resistance and Endurance Exercise in ALS**
John's Hopkins University
PI (\$43,862)
The goal of the trial is to evaluate resistance and endurance exercises in ALS patients.
- 2012-2014 **Validation of a self-report scale for the assessment of bulbar function**
ALS Association 2106B
Co-Investigator (\$269,981)
Develop outcome measures for ALS
- 2012-2016 **NeuroNEXT-SMA Biomarkers in the Immediate Post-Natal Period of Development**
NINDS U01NS079163
Clinical Coordination Center PI (\$934,892)
The primary objective of this study will focus upon the natural history of SMA biomarkers in the immediate postnatal period of development.
- 2012-2017 **Environmental Risk Factors for ALS in a Representative Sample of the US**
President and Fellows of Harvard, R56NS08210
PI (\$33,870)
A study of possible environmental risk factors for ALS.
- 2013-2016 **Noninvasive assessment of neuromuscular disease using electrical impedance**
R44 NS070385
Co-Investigator (\$378,095)
NCRI will provide support for project and data management, and biostatistical support.
- 2013-2017 **Multi-Center, Randomized Controlled Study of the NeuRX Diaphragm Pacing System in Participants with ALS**
ALS Association (SUNY)
PI of Coordination Center (\$450,000)
The NCRI Coordination Center is responsible for the overall project management of all study activities.
- 2013-2017 **Multi-Center, Randomized Controlled Study of the NeuRX Diaphragm Pacing System in Participants with ALS**
Synapse (SUNY)
PI of Coordination Center (\$912,168)

- The NCRI Coordination Center is responsible for the overall project management of all study activities.
- 2013-2018 **NeuroNEXT-Ibudilast Phase II Trial in Progressive MS**
 Cleveland Clinic (Fox, R PI); U01 NS082329
 Clinical Coordination Center PI (\$5,526,813)
 This study proposes to both test the activity of a potential neuroprotection therapy - ibudilast -in progressive MS and test several candidate imaging measures for their utility in future studies of neuroprotection in progressive MS.
- 2013-2018 **NeuroNEXT-Rituximab in the management of refractory autoimmune MG**
 Yale University (Nowak, R PI); U01NS084495
 Clinical Coordination Center PI (\$2,641,456)
 The primary aim of this study is to determine whether rituximab is safe and shows sufficient promise as a steroid sparing therapeutic for MG to warrant further study in a phase III efficacy trial.
- 2014-2016 **NeuroNEXT-Rituximab in the management of refractory autoimmune MG**
 Yale University (Nowak, R PI); U01NS084495
 Clinical Coordination Center PI (\$2,641,456)
 The primary aim of this study is to determine whether rituximab is safe and shows sufficient promise as a steroid sparing therapeutic for MG to warrant further study in a phase III efficacy trial.
- 2015-2017 **Proof-of-concept study of RNS60 in ALS** (PI Paganoni, S, MGH)
 Philanthropy
 Co-PI (\$694,000)
 The objective of this proof-of-concept study is to measure the effects of RNS60 on reducing brain microglial activation measured by [11C]-PBR28-PET and its effects on peripheral immune markers in 15 people with Amyotrophic Lateral Sclerosis (ALS). We will also assess safety and effects on clinical measures of illness.
- 2014-2018 **A Phase II Randomized Placebo-controlled Trial of Tocilizumab in ALS** (PI Ladha, S, Barrows Neurological Institute)
 The Amyotrophic Lateral Sclerosis Association (Foundation); 15-TACL-187 (\$154,508)
 Philanthropy (\$500,000)
 Co-PI Coordination Center
 The primary aims of this project are to determine the safety and tolerability of up to 8mg/kg per month of tocilizumab in ALS and to demonstrate the attenuation of pro-inflammatory pathways that play a role in motor neuron death in ALS. Secondary aims are to demonstrate the pharmacokinetics of the study drug in blood and CSF, as well as to preliminarily assess for an efficacy signal.
- 2014-2018 **A Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of SYN120, a dual 5-HT6/5-HT2A Antagonist, in Parkinson's Disease Dementia**
 Biotie Therapies Inc (Michael J Fox Foundation)
 Coordination Center PI:(\$3,494,000)
 Evaluate the safety, tolerability and efficacy of SYN120 in PDD patients.
- 2014-2018 **NeuroNEXT Trial: ZZ-3K3A-201: Safety Evaluation of 3K3A-APC in Ischemic Stroke**
 Cedars-Sinai Research Institute (Lyden, P PI), U01NS088312
 Clinical Coordination Center Director (\$3,437,014)
 An evaluation of the safety of 3K3A-APC in Ischemic Stroke.

- 2014-2018 **Autologous Regulatory T Lymphocyte Therapy in ALS**
ALS Finding a Cure (Foundation)
Coordination Center PI: Cudkowicz (\$180,000)
The primary objective of the first stage of the pilot study is to determine the safety and tolerability of infusions of autologous Treg cells in 2 patients with ALS. The secondary objective will be to determine whether the administration of autologous Treg cells with or without concomitant subcutaneous IL-2 therapy increases the number of Treg cells in peripheral blood in ALS patients.
- 2014-2018 **Phase 2 pharmacodynamic study of retigabine on neuronal excitability in ALS Subjects**
ALS Association TACL-215
Coordination Center PI (Study PI: Wainger, B)
The major goals of this project are to measure effect of retigabine on motor neuron excitability, determine safety, dosing and pharmacokinetics of retigabine in ALS subjects and obtain skin biopsies for iPSC motor neuron differentiation and *in vitro* motor neuron physiological profiling
- 2014-2019 **Inflammatory Biomarkers, Stem Cells, and DNA in People with ALS (ENROLL)**
ALS Association / ALS Finding a Cure (Atassi)
Co-Investigator
The major goal of this project is a study in the inflammatory Biomarkers, stems cells, and DNA in people with ALS. This project aspires to identify biomarkers of ALS that will give us clues to disease mechanisms and help us identify targets for ALS therapy development.
- 2014-2020 **Safety and Tolerability Study of AAV10-mediated, miRNA-based silencing of the SOD1 gene in Patients with SOD1-mediated Familial Amyotrophic Lateral Sclerosis**
ALS Finding a Cure (Foundation)
Coordination Center PI (\$45,600)
The primary objective of the study is to determine the safety and tolerability of this therapy.
- 2015-2017 **Proof-of-concept study of RNS60 in ALS** (PI Paganoni, S, MGH)
Philanthropy
Co-PI (\$694,000)
The objective of this proof-of-concept study is to measure the effects of RNS60 on reducing brain microglial activation measured by [11C]-PBR28-PET and its effects on peripheral immune markers in 15 people with Amyotrophic Lateral Sclerosis (ALS). We will also assess safety and effects on clinical measures of illness.
- 2015-2018 **Effects of mexiletine on cortical hyperexcitability in amyotrophic lateral sclerosis**
(PI: M. Weiss, University of Washington) ALS Association 16-TALS-298
Philanthropy (\$500,000)
Clinical Coordination Center PI
The objective of this phase 2 study is to determine the effects of mexiletine on cortical hyperexcitability in ALS participants using transcranial magnetic stimulation. Stem cells secreting GDNF for the treatment of ALS
- 2015-2018 **NeuroNEXT-Tolerability of SRX246 in Huntington's Disease**
Azevan/MGH (Goldstein, M PI) 4U44NS090616
Clinical Coordination Center PI (\$2,940,977)
The study goal is the test the effect of SRX246 on irritability in people with Huntington's Disease.
- 2015-2018 **Phase 3 trial of inosine for Parkinson's Disease**

- U01NS090259 (MGH Schwarzcchild, M PI)
Co-PI (Clinical Coordination Center)
The major goal of this project is to determine whether inosine dosed to raise serum urate levels slows clinical progression in early Parkinson's Disease.
- 2015-2020 **DR2A-05320; Cedars Sinai Research Institute (CIRM grant)**
Sub-Award PI data coordinating center (PI Svendsen, C)
The primary goal of this project is to help with the study of human neural progenitor cells expressing glial cell line derived neurotrophic factor (CNS10-NPCGDNF) for the treatment of ALS
- 2016-2018 **Massachusetts ALS Partnership Program (MAPP) (Co-Directors: Berry and Atassi)**
ALS Association, ALS Finding a Cure and ALS One (Foundations)
Investigator (\$1,800,000)
The primary goals of this program are to: 1- Build an efficient regional ALS clinical trials network to translate promising lab findings into treatments for people with ALS. 2- Build a translational pipeline that includes the development of new lab tests and imaging tools to efficiently test treatment effects in ALS patients, and the expansion of a clinical trial of a medication (Ibudilast) that targets inflammation as one of the proposed ALS mechanisms. 3- Move the multidisciplinary care at MGH beyond the walls of the clinic to improve access and integrate with Compassionate Care ALS (CCALS) and other home care providers using novel technology and nursing resources.
- Current*
- 2011-2023 **NeuroNEXT Clinical Coordination Center**
NINDS, U01NS077179
PI (\$7,499,997 total direct costs)
The primary object is to act as the Clinical Coordinating Center for a NINDS sponsored 25 site Network, to conduct efficient, high impact, and high-quality studies. Additional objectives include education and training of clinical investigators and staff at each site.
- 2015-2021 **Answer ALS (PI: Rothstein/Berry)**
ALS Finding a Cure (Foundation)
Co-Director (\$546,713 total direct costs)
ANSWER ALS is designed to generate iPS brain cells from a large population of ALS patients to comprehensively evaluate their genetic and metabolic profiles and perform comprehensive longitudinal clinical observations.
- 2016-2021 **NeuroNEXT- Cytochrome C Oxidase: Biomarker in Newly Diagnosed Glioblastoma Multiforme**
University of Iowa (Griguer, C PI) U01NS093663
Clinical Coordination Center PI (\$863,580 total direct costs)
The primary objective of this study is to evaluate the hypothesis that overall survival time of participants with newly diagnosed GBM tumors are a function of CcO enzymatic activity in the tumor.
- 2016-2021 **NeuroNEXT-Effects of AFQ056 for Language Learning in Children with FXS**
Rush University Medical Center (Berry-Kravis, E PI) U01NS096767
Clinical Coordination Center PI (\$5,603,338 total direct costs)
The primary objective of this study is to evaluate the effect on language in young children with FXS treated with AFQ056 in combination with an intensive, standardized parent implemented language intervention.
- 2017-2021 **NeuroNEXT- Topiramate as a Disease Altering Therapy for CSPN**
Virginia Commonwealth University (Smith, G PI) U01NS095388

- Clinical Coordination Center PI (\$3,477,385 total direct costs)
The primary objective is to determine if topiramate slows progression of cryptogenic sensory polyneuropathy (CSPN).
- 2017-2022 **Collaboration to Develop an ALS Clinic and Clinical Trials in ALS**
Holy Cross Hospital
PI (\$1,352,642 total direct costs)
The primary goal is to provide consultation, clinical assistance and professional support in the development and implementation of research and clinical activities dedicated to the study and treatment of patients with neurological illnesses, disorders and conditions at the Smith ALS Clinic at Holy Cross Hospital.
- 2017-2023 **NeuroNEXT - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE Myopathy**
Brigham & Women's Hospital (Amato & Carrillo PI) U01AR070498
Clinical Coordination Center PI (\$2,531,682 total direct costs)
The primary objective of this study is to evaluate the efficacy of ManNAc in participants with GNE myopathy as measured by the ability to slow the progression of muscle strength decline compared to placebo. This study is a collaboration between NINDS and NIAMS.
- 2018-2021 **Expanded Population of Regulatory T-Cells (EPAR T-Cells) for People with Amyotrophic Lateral Sclerosis (PALS)**
ALS Association | ALS Finding a Cure
Co-Investigator (\$750,000 total direct costs)
The primary aims of this study are to evaluate the biological activity of IV infusion of an expanded population of autologous regulatory (EPAR T-Cells) and low-dose IL-2 in people with ALS by evaluating Treg number and suppressive function; to evaluate the safety and tolerability of IV infusion of an expanded population of autologous regulatory T-cells (EPAR T-Cells) and low-dose IL-2 in people with ALS; and to characterize the effects of EPAR T-Cells and low-dose IL-2 on clinical outcome measures of ALS including Appel ALS Scale (AALS) and ALS Functional Rating Scale-Revised (ALSFRS-R) scores.
- 2019-2022 **NeuroNEXT - A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease**
MGH (Videnovic PI) U01NS114001
Clinical Coordination Center PI (\$2,644,099 total direct costs)
The primary objective of this study is to examine the optimal dose frequency of LT to improve sleep in PD and carry forward in future clinical trials.
- 2020-2022 **ALSA Clinical Trial Support**
ALS Association
PI (\$352,416 total direct costs)
The primary objective of this study is to 1) Support Therapeutic Pipeline Development 2) Develop and Promote Quality Clinical Trials and 3) Enhance Clinical Trial Access and Participant Recruitment, Retention, and Experience
- 2019-2024 **HEALEY ALS Platform Trial | Accelerating the Path to Effective Treatments for ALS**
ALS Association, PI (\$2,608,696 total direct costs) | Jan 2020 to Dec 2022
ALS Finding a Cure, PI (\$1,391,304 total direct costs) | Apr 2020 to Mar 2022
Muscular Dystrophy Association, Co-I (\$454,545 total direct costs) | Apr 2021 to Mar 2024
M. Blank Family Foundation, PI (\$500,000 total direct costs) | Dec 2019 to Nov 2021

UCB/Ra Pharmaceuticals, Inc., PI (\$9,497,075 total direct costs) | Oct 2019 to Apr 2023
 Biohaven Pharmaceuticals, Inc., PI (\$9,933,104 total direct costs) | Oct 2019 to Apr 2023
 Clene Nanomedicine, Inc., PI (\$6,164,018 total direct costs) | Oct 2019 to Dec 2021
 Prilenia Neurotherapeutics Ltd., PI (\$9,461,538 total direct costs) | Nov 2019 to Jun 2022
 Seelos Therapeutics, Inc., PI (\$9,085,372 total direct costs) | Jan 2021 to Jun 2023
 Revalerio, Inc., PI (\$486,055 total direct costs) | Jan to May 2021

The primary objective of this phase 2/3 perpetual multi-center, randomized, placebo-controlled, clinical trial is to evaluate the safety and efficacy of multiple investigational products for the treatment of ALS. Several investigational products will be tested in parallel and sequentially, using a shared infrastructure, common data and sample collection processes, and central governance.

Report of Local Teaching and Training

Teaching of Students in Courses

2000	Epidemiology 208 Literature Critique HSPH Students	HSPH Guest speaker three hours
2004	EPI 284c Epidemiology of Neurological Diseases HSPH Students	HSPH Guest speaker five hours
2001	HST 160 Molecular Biology and Genetics in Modern Medicine 1 st year medical students	HST Supervised 3 students ten hours
2006, 2010	HST 11 The Art and Science of Medicine MIT undergraduate students	HST Guest speaker 20 students six hours
2008, 2009, 2011, 2012	HST 130 Introduction to Neuroscience 2 nd year medical students	HST Guest speaker Three hours once per year
2019	HST MD Introduction to the Profession for Physician-Scientists	HST MD

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2001	Neuroepidemiology Neurology residents	MGH and BWH One hour lecture per month for a year
2008-2010	Neuroscience Seminar Series Neurology residents	MGH and BWH One hour lecture
2009	Drug development in ALS Clinical research fellows	BIDMC, Clinical Investigator Training Program Two and half hours lecture
2009-2011	Becoming a Principal Investigator for multi-center clinical trials Clinical research fellows	MGH Five hours lecture
2011	Resident Neuroscience Journal Club Neurology residents and fellows	One and half hours
2012-	Chief Resident Rounds MGB residents and fellows	2 hours/month

Clinical Supervisory and Training Responsibilities

1996-	Neurology Ambulatory Care Clinic Preceptor MGH	Four to five half sessions per week
1996-2007	Neurology Inpatient Unit Attending physician MGH	Four weeks per year
2005-	Neuromuscular Ambulatory Care Clinic Preceptor MGH	One half session per week
2007-2011	Neurology Inpatient Unit Attending physician MGH	Two weeks per year

Laboratory and Other Research Supervisory and Training Responsibilities

2008-	Supervision of research fellow/ALS	Daily mentorship for twelve months of one-two non-US trained MD research fellows
2009-2011	Supervision of Spaulding Rehabilitation Hospital Resident in Research	Monthly meetings

Formally Supervised Trainees

2001-2008	Mudasir Qureshi, MD/Pediatric Resident, Texas Tech University Health Science. Published six first author papers, one review and one meeting proceedings paper.
2002-2004	Bryan Traynor, MD, MMSc, MRCPI/ Chief Neuromuscular Diseases Research Group NIA, NIH. Clinical Investigator Training Program fellowship awardee; Published two first author papers; faculty position at NIH and adjunct faculty position at John Hopkins University.
2004-2005	Rabia Choudry, MD/Staff Neurologist, Baylor University Medical Center. Published up-to-date manuscript on ALS. Developed ALS center in Texas.
2005-2007	Allitia Dibernardo, MD/Medical Director Johnson and Johnson. Published important pharmacodynamic study of Creatine in ALS. Leading development of new treatments for neuromuscular disorders. Senior Medical Director of US Affairs at Novartis Pharmaceuticals Corporation.
2006-2009	Anne Marie Wills MD MPH/Assistant Professor of Neurology, HMS. 2006 American Academy of Neurology/ALS Association Clinician Scientist Development Awardee, 2009 Muscular Dystrophy Association Neuromuscular Clinical Research Fellowships. Published two important papers on genetics of ALS.
2006-2009	Leigh Hochberg, MD PhD/Visiting Associate Professor of Neurology, HMS. Professor Brown University. Multiple published articles on use of brain chips for communication for patients with ALS and spinal cord injury. Invited plenary speaker at American Academy of Neurology.
2007-2010	Swati Aggarwal, MD/ 2009 American Academy of Neurology, ALS Association Clinician Scientist Development Awardee. Published pivotal clinical trial paper in Lancet Neurology.

2008-2019 Nazem Atassi, MD MSc/Associate Professor of Neurology, HMS.
Clinical Scholars Program graduate, T32 award, Muscular Dystrophy Association
Clinical Research Fellowship. Biogen-Idec ABY Fellowship, K23. VP Sanofi

2010- James Berry, MD MSc/Associate Professor of Neurology, MGH.
T32 award, Muscular Dystrophy Association Clinical Research Fellowship, AAN Rick
Olney ALS Clinical Research Fellowship, Neurology Department Merit Awardee 2011.

2010 Steve Han, MD PhD/Assistant of Neurology, HMS, Medical Director Takeda, Clinical
Investigator Training Program Fellow, 2011 American Academy of Neurology/ALS
Association Clinician Scientist Development Awardee, KL2 MeRIT Awardee 2012.

2010- Sabrina Paganoni, MD PhD/Assistant Professor of Physical Medicine and Rehabilitation,
HMS, K12 Rehabilitation Medicine Scientist Training Awardee.

2012-2016 Haruhiko Banno, MD PhD/ Clinical Research Fellow, MGH.

2012-2016 Elena Ratti, MD/ Instructor, HMS, Biogen-Idec ABY Fellowship, Biogen Associate
Medical Director

2014- Katie Nicholson, MD/Instructor, HMS, Biogen ABY Fellowship

2016- Suma Babu MD/Assistant Professor Neurology, HMS, AAN Clinical Research
Fellowship

2017-2021 Sheena Chew, MD/Instructor, HMS, Biogen ABY Fellowship; Currently Biogen MD

Formal Teaching of Peers (e.g., CME and other continuing education courses)

1994, 1996,	Intensive Review of Neurology	Lecture
1997, 2008	Neurology, Harvard Medical School	Boston
1999, 2001	Electromyography and Clinical	Lecture
2009, 2010	Neurophysiology	Boston
	Harvard Medical School	
2011	Principles and Practice of Clinical Research	Lecture
	Harvard Medical School	Boston and web-based
2011	Managing Your Team, Harvard Catalyst	Invited Speaker
		Boston
2012	The Study Team, NEALS	Invited Speaker
	New Principal Investigator Training	Charlestown

Local Invited Presentations

2001 Remacemide and Coenzyme Q10 Therapy in Huntington’s Disease/ Invited Speaker
General Clinical Research Center

2002 Results of CARE-HD trial/ Speaker Series
Department of Neurology, MGH

2002 Genetics of ALS/ Speaker Series
Massachusetts General Physician Organization

2002 Translational research in ALS/ Grand Rounds
Department of Neurology, MGH

2003 Harvard Clinical Trial Service/ Update
Harvard Center Neurodegeneration and Repair

2004 How to fund clinical trials/ Lunchtime Speaker Series
Department of Neurology, MGH

- 2004 How do we find treatments for ALS/ Grand Rounds
Department of Neurology, MGH
- 2008 ALS a Brave New World/ Speaker
Harvard Medical School Alumni Week
- 2008 Translation towards effective ALS therapy/ Update
MGH Chief's council
- 2004 How to fund clinical trials/ Lunchtime Speaker Series
Department of Neurology, MGH
- 2008 Lost and found in translation: ALS/ Update Neurology Retreat
Department of Neurology, MGH
- 2010, 2011 IND/IDEs – Beyond the basic investigational product applications/ Speaker Series
Clinical Research Education Unit, MGH
- 2010, 2011 Sponsoring and Managing Multi-Center Clinical Trials/ Speaker Series
2011 Clinical Research Education Unit, MGH/ Speaker
MGH Bicentennial Celebration
- 2012 ALS: New Genes, New Treatments and Renewed Hope/ Grand Rounds
Brigham and Women's Hospital
- 2012 Drugs, gene therapy, stem cells: Therapeutic revolution in ALS/ Invited Plenary Speaker
New England Science Symposium, Harvard Medical School
- 2012 ALS Care: Tackling Symptoms and Disease Progression/PalliativeCare/ Grand Rounds
MGH
- 2012 From Chemical Engineering to Clinical Department Chair: Lessons learned as a Woman
in Academic Medicine/ Invited Speaker
Office for Women's Careers, MGH
- 2014 Update on ALS Clinical Trials/ Grand Rounds
Newton-Wellesley Hospital, Newton, MA
- 2015 ALS Research and Treatment Advancements/ Spring HST Dinner Seminar/ Invited
Speaker
Harvard Club of Boston
- 2015 MGH Clinical Research Day: How to think about innovation and translation at MGH/
Invited Panel Speaker
MGH
- 2018 Developing Effective ALS Therapies: Lessons From Recent Clinical Trials/ Invited
Speaker
CellPress LabLinks
- 2018 C/T Academy Research Day: Graduation Address/ Invited Keynote Speaker
The Harvard Clinical and Translational Science Center
- 2020 New Advances in ALS, ECOR presentation with Dr Clotilde Lagierre Tourenne
- 2021 Life Post Residency, Choosing Best Position & Academic Medicine / Invited Speaker
Neurology Department, Massachusetts General Hospital, Boston, MA

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

Regional

- 1996, 2005 ALS Clinical Trials/ Grand Rounds
Beverly Hospital, Beverly, MA

- 2002 Update on mouse and human studies in ALS/ Invited Speaker
MDA Regional Science Meeting, Charlestown, MA
- 2003 Experimental therapies in ALS/ Grand Rounds
Boston University School of Medicine, Boston, MA
- 2004 Novel Therapies for ALS/ Invited Speaker
University of Massachusetts, Worcester, MA
- 2006 How to launch a clinical trial/ Invited Speaker
Northeast ALS consortium 5th Annual Meeting, Boston, MA
- 2007 Safety and dose escalating study of oral sodium phenylbutrate in subjects with ALS
(abstract) Treatment of ALS / Course Lecture Neuromuscular Therapy/ Invited Speaker
American Academy of Neurology 59th Annual meeting, Boston, MA
- 2008 ALS clinical trials; designs and challenges/ Invited Speaker and Course organizer
China ALS Training Course, Boston, MA
- 2009 Update on ALS Therapeutics/ Grand Rounds
Tufts Medical School, Boston, MA
- 2011 State of Therapeutic Development in ALS/
Massachusetts Biotechnology Society, Cambridge, MA (Prize4Life)
- 2011 ALS Innovation Award Meeting
Cambridge, MA
- 2012 New England MDA Clinic Directors' Meeting/
Charlestown, MA
- 2013 ALS: New Directors/
ALS Research Day, Lexington, MA (Shire Pharmaceuticals)
- 2014 ALS Update/ Invited Speaker
Head Health Initiative. NFL Headquarters, New York, NY
- 2015 ALS Therapeutic Advances/ Grand Rounds
New York University, New York, NY
- 2015 Clinical Demonstrations/ Moderator
World Medical Innovation Forum, Boston, MA
- 2015 Neurocare, Neuromarkets, and Neuro Challenges/ Panelist
World Medical Innovation Forum, Boston, MA
- 2015 Solving ALS: Lessons from Multiple Disciplines/ Invited Speaker
10th Annual HSCI Malkin Retreat, Cambridge, MA
- 2020 Career Advice: Life After Residency, Finding a Job and Starting a Career in Academic
Medicine./ Invited Speaker.
Massachusetts General Hospital Resident's Conference. Virtual Lecture, Boston, MA
- 2020 2020 ALS ONE Research Symposium: 2020 View of ALS Therapeutics.
ALS ONE, MA

National

- 1996 Intrathecal SOD1 as a treatment for ALS/ Invited Speaker
Pharmaceutical Research and Manufacturers of America Foundation Meeting,
Washington DC
- 1997 Riluzole therapy in Huntington's Disease/ Invited Speaker
Huntington's Disease Study Group Annual Meeting, Santa Fe, NM
- 1998 Superoxide dismutase 1 and ALS/ Grand Rounds
Yale University, Department of Neurology, New Haven, CT
- 1998 Riluzole therapy in patients with Huntington's disease/ Invited Talk
American Academy of Neurology 50th Annual Meeting

- 1999 Recent advances in the treatment of ALS/ Invited Speaker
Columbia University Sergievsky Center, New York, NY
- 1999 Effects of altered levels of GSHPx on disease phenotype in the ALS mouse model/
Invited Speaker
The Banbury Center, ALS Association Scientific Workshop, Cold Spring Harbor, NY
- 2000 Therapeutic advances in ALS/ Invited Speaker
Medtronic Inc. CNS Infusion Board Meeting (Medtronic)
- 2000 Clinical trial of Minocycline in HD/ Invited Speaker
Huntington's Disease Study Group Annual Meeting, La Jolla, CA
- 2000 Will Topiramate slow disease progression in ALS?/ Invited Speaker
Epilepsy Conference, New Orleans, LA (Ortho-McNeil)
- 2000 Clinical Trial of Celebrex in ALS/ Invited Speaker
Pfizer Pharmacia New Initiatives meeting, Philadelphia, PA (Pfizer Pharmacia)
- 2001 Study design methodology in ALS. Experience of the Northeast ALS Consortium/
Invited Speaker
ALS Association Drug Company Working Group Meeting, Denver, CO
- 2001 Therapeutic advances in ALS/ Grand Rounds
State University of New York, Upstate Medical University, Syracuse, NY
- 2002, 2006 Experimental therapeutics in ALS/ Invited Speaker
ALS Association Clinical Conference/Leadership Conference, Washington DC
- 2002 Clinical trial of Topiramate in ALS: Risk for abnormal clotting events/ Invited Speaker
Ortho-McNeil experts panel on ALS and deep venous thrombosis (Ortho-McNeil)
- 2003 Clinical outcome measures in ALS/ Invited Speaker
Tarrytown ALS Research Meeting, Tarrytown, NY
- 2003 ALS: From the mouse colony, to the bedside and back again/ Plenary Invited Speaker
American Neurological Association, San Francisco, CA
- 2004 New drug therapies in ALS/ Invited Speaker and Participant
NINDS/ALS Association Drug Discovery Workshop, New York City, NY
- 2004 ALS Diagnosis and Management, ALS Lessons from genetics and new treatment
initiatives, and Huntington's Disease, a double blind futility study of Minocycline in HD
Fifth Annual Jules Schwartz ALS Lecture/ Visiting Professor
University of Rochester, Rochester, NY
- 2004 Celebrex clinical trial/ Invited Speaker
Jazz Pharmaceutical ALS Advisory Board Meeting, Scottsdale, AZ
- 2004 Outcome measures in ALS/ Invited Plenary Speaker
American Academy of Electromyographers 51st Annual Meeting, Savannah, GA
- 2004 Challenges of clinical investigation/ Invited Speaker
Huntington's Disease Study Group 12th Annual Meeting, St Louis, MO
- 2004 Novel therapies in ALS/ Grand Rounds
Brown University, Department of Neurology, Providence, RI
- 2005 New approaches to ALS therapies/ Invited Speaker
Packard Center Board Meeting, New York City, NY
- 2005 Clinical study designs in Huntington's disease/ Invited Speaker
HiQ Foundation Scientific Advisory Board Meeting, New York City, NY
- 2006 Therapeutic advances in ALS/ Grand Rounds
Cornell Medical School, New York City, NY
- 2006 Clinical trial design in ALS studies/ Invited Speaker
ALS Association Drug Company Working Group meeting, San Diego, CA

- 2006 Clinical Research Career Options/ Invited Speaker
American Academy of Neurology, San Diego, CA
- 2006 Neuromuscular Scientific Highlights/ Invited Presenter
American Academy of Neurology 58th Annual Meeting, San Diego, CA
- 2006 Northeast ALS Consortium clinical research initiatives/ Invited Speaker
Packard Center Annual Meeting, Baltimore, MD
- 2006 Challenges in biomarkers and trial designs for SMA and ALS/ Invited Speaker
Neurobiology of Disease Workshop, Motor Neuron Disease, Atlanta, GA
- 2007 ALS: causes and cures/ Grand Rounds
University of Pennsylvania, Philadelphia, PA
- 2007 ALS 2007: Symptomatic management and new therapeutic options/ Invited Speaker
Lunch and Learn Sessions, Web based conference (NINDS)
- 2008 Update on current and ongoing clinical trials/ Invited Speaker
Overview of clinical trials in ALS/ Invited Speaker
ALS Association TREAT ALS Conference, Tampa, FL
- 2008 ALS medicines and mechanisms/ Grand Rounds
Albert Einstein, New York City, NY
- 2008 ALS diagnosis, management and clinical trial designs/ Invited Speaker
KNOPP/Omnicare ALS orientation and training symposium (KNOPP)
- 2008 ALS Therapy Development: A Brave New World/ Invited Plenary Speaker
American Society for Experimental NeuroTherapeutics 10th Annual Meeting, Arlington, VA
- 2008 Northeast ALS Consortium clinical trial initiatives/ Invited Speaker
Packard Center Annual Meeting, Baltimore, MD
- 2008 TREAT ALS NEALS clinical trial network/ Invited Speaker
ALS Association Drug Company Working Group, Chicago, IL
- 2009 Clinical Trials Update: Ceftriaxone/ Invited Plenary Speaker
Muscular Dystrophy Association National Clinic Directors Conferences, Las Vegas, NV
- 2009 Lessons learned from past trials in ALS/ Invited Speaker
Muscular Dystrophy Association Phase 2 trial design workshop, Washington DC
- 2009 ALS treatment trials: bridge from science to cures/ Plenary Talk, Sheila Essey Award
Lecture
American Academy of Neurology, Seattle, WI
- 2009 ALS therapeutics: lessons learned and path forward/ Grand Rounds
Emory University, School of Medicine, Atlanta, GA
- 2009 Successful participation in multi-institutional studies.
Where do I go from here?/ Invited Speaker
American Neurological Association Summer Course in Clinical and Translational
Research Vail
- 2009 Phase 2 trial designs/ Invited Speaker and Course Co-Director
Clinical Trials Method Course in Neurology, Vail (NINDS)
- 2009 Adaptive Clinical Trials: Ceftriaxone in ALS a seamless adaptive design study/Invited
course faculty
Huntington's Disease Study Group Annual Meeting, Baltimore, MD
- 2010 ALS treatments symptomatic and neuroprotective/ Grand Rounds
Medical University of South Carolina, Charleston, SC

- 2010 A 12 week phase 2 study of the safety, tolerability and clinical effects of KNS760704 in ALS/ Invited Speaker
10th Annual Robert Packard Center ALS Research Symposium, Baltimore, MD
- 2010 KNS760704 Part 2 Study Results/ Invited Speaker
Knopp Neuroscience Webcast
- 2011 EMPOWER Investigator Meeting; Principal Investigator
ALS clinical trial updates
Phase 2 Dexamipexole results and Phase 3 design
Recruitment and Retention Strategies,
Atlanta and Amsterdam, GA
- 2011 Research Career Development Symposium: Transitioning from Residency to Research/
Invited Speaker
American Academy of Neurology 63rd Annual Meeting, Honolulu, HI
- 2011 ALS Therapies-The Road to a Cure/ Grand Rounds
University of Arkansas, Little Rock, AK
- 2011 Careers in Clinical Research/ Invited Speaker
University of Arkansas, Little Rock
- 2012 Clinical trial of Ceftriaxone in ALS: Final results/ Invited Speaker
International Motor Neuron Disease Symposium, Chicago, IL
- 2012 Fellowship Recipient Announcement/ Moderator
American Academy of Neurology 64th Annual Meeting, New Orleans, LA
- 2012 The Empower Study: Design, Methodology and Baseline Features of the First Phase III
Clinical Trial of Dexamipexole for Patients with ALS/ Invited Speaker
American Academy of Neurology 64th Annual Meeting, New Orleans, LA
- 2012 ALS Therapy Development-Progress and Hope/ Invited Speaker
Amytrophic Lateral Sclerosis: Trials, Treatments, and Tribulations Conference
Hospital For Special Care, New Britain, CT
- 2012 University of Pennsylvania/ Grand Rounds
Philadelphia, PA
- 2012 12th Annual Packard Center Symposium/ Invited Speaker
Ceftriaxone and Dexamipexole Phase III ALS studies, Baltimore
- 2012 ALS Therapy Development-Progress In Therapy/ Invited Speaker
Yale School of Medicine, New Haven, CT
- 2012 ALS Therapeutic Advances/ Invited Speaker
Fifth Stanley H Appel Resident Education Distinguished Lecture, Methodist Hospital,
Houston, TX
- 2012 ALS Update on Therapy Development/ Invited Speaker
MDA South Regional Meeting, Houston, TX
- 2013 University of Pittsburgh Medical Center/ Grand Rounds
The Leonard Gerson Distinguished Scholar Lecture, Pittsburgh, PA
- 2013 19th William L. Halseth ALS Visiting Professor/ Grand Rounds
University of Colorado Anschutz Medical Campus, Denver, CO
- 2013 Clinical Trials Plenary Session/ Invited Speaker
American Academy of Neurology 65th Annual Meeting, San Diego, CA
- 2013 The 29th Irwin Levy Visiting Lectureship/ Grand Rounds
Washington University in St. Louis, St. Louis, MO

- 2013 5th Annual Translational and Clinical Research Course for Clinician-Scientists/
American Neurological Association
- 2013 Focus Group Leadership Meeting
Washington, DC (ALSA/NEALS)
- 2013 Leaders in the Field Presentation: SIG Meeting. Presymptomatic Therapy in ALS/
Invited Speaker
American Neurological Association, New Orleans, LA
- 2013 C9ID Meeting/ Invited Speaker
Norfolk, VA
- 2013 ALS Therapeutic Revolution-small molecules, gene, and stem therapy/ Petajan Lecture
Series
University of Utah, Salt Lake City, UT
- 2014 14th Annual Robert Packard Center for ALS Research Symposium
NEALS/ Update on enrollment, active NEALS studies and initiatives
Baltimore, MD
- 2014 Inaugural Resident/ Invited Grand Rounds Speaker
ALS: Changing Definition and Approach to Therapy Development
Department of Neurology, University of Washington, Seattle, WA
- 2014 Swedish Neuroscience Grand Rounds
ALS: Therapeutic: New Frontier
Seattle, WA
- 2014 New Therapeutic Approach to ALS/ Grand Rounds
University of Rochester Medical Center, Rochester, NY
- 2014 Leading multicenter clinical trials/
ANA-TCRC Meeting, Chicago, IL
- 2014 Clinical Trials Methodology Course “Selecting Outcome Measures for Neuroscience
Trials” and “Clinical Trials Networks: NeuroNEXT”
Iowa City, IA (NINDS)
- 2014 ANA Career Development Symposium/ Chair Panel/ Mentor
Baltimore, MD (NINDS)
- 2014 Overview of Challenges for Clinical Trials/ Investigator Research Workshop
Philadelphia, PA (ALSA)
- 2014 2 Care Close Out Meeting
Minneapolis, MN (Huntington Study Group)
- 2015 ALS Therapeutics/ Oh Lectureship/ Grand Rounds
University of Alabama Birmingham, Birmingham, AL
- 2015 ALS Clinical Trials and Why Have They Failed/ Invited Speaker
American Academy of Neurology 67th Annual Meeting, Washington, DC
- 2015 ALS – Update on Therapeutics/NINDS/NIH Clinical Neuroscience Grand Rounds/
Invited Speaker
NIH, Bethesda, MD
- 2015 ALS Update on Therapeutics/ Grand Rounds
Northwestern Medical Hospital, Chicago, IL
- 2015 2015 ALS Therapeutics – Opportunities and Challenges/ Grand Rounds
Johns Hopkins, Baltimore, MD
- 2015 After the ALS ice bucket challenges – hope in therapeutic development/ Grand Rounds/
Invited Speaker
Dartmouth Hitchcock Medical Center, Hanover, NH

- 2015 2015 ALS Therapeutics – Opportunities and Challenges/ Grand Rounds/ Invited Professorship
Mayo Clinic, Rochester, MN
- 2016 Clinical trials in neurodegenerative disorders: Lessons from ALS and HD/ Invited Speaker
National Ataxia Foundation, Orlando, FL
- 2016 ALS 2016 – New Therapies and Direction/ Grand Rounds/ Invited Speaker
SUNY Downstate Medical Center, Brooklyn, NY
- 2016 ALS Therapeutics/ Grand Rounds/ Aring Invited Lecturer
University of Cincinnati, Cincinnati, OH
- 2016 Conducting Clinical Trials in an Academic Neurology Setting/ Invited Speaker
8th Annual Translational and Clinical Research Course for Clinician-Scientists
American Neurological Association, Chicago, IL
- 2016 Biomarkers/ Invited Speaker
Clinical Trials Methodology Course
NINDS, Ann Arbor, MI
- 2016 Stem Cell Therapy, RNA and Gene Therapy in ALS/ Invited Speaker
AANEM Annual Meeting
New Orleans, LA
- 2016 Developing Multidisciplinary Clinics for NM Care and Research/ Plenary Speaker
Richard Olney Presentation; AANEM Annual Meeting
New Orleans, LA
- 2016 NINDS/ANA Career Development Symposium/ Invited Speaker
Baltimore, Maryland
- 2017 2nd CNS Clinical Trials Forum/Invited Speaker
Explore Efficient Networks to better position your trial for success. Philadelphia, PA
- 2017 National Institute of Aging/Invited Speaker
ALS – new therapeutics and efficient networks, Baltimore, Maryland
- 2017 Northeast ALS Consortium/Invited Speaker
Overall Principal Investigator Responsibility, Phoenix, AZ
- 2017 American Academy of Neurology Invited Speaker
Keynote Talk: Keys to success in academic neurology
Research Corner: Grant applications: Working with your Chair and/or grant team from application to conclusion
- 2017 ALS: New Insights into Biology and Treatments/Grand Rounds Invited Speaker
University of Iowa, Iowa City, IA
- 2017 ALS: New treatments and Insights/Invited Speaker
7th Annual Stanley van den Noort Lecture, University of Irving, Irving, California
- 2017 American Neurological Association Invited Speaker
Translational and Clinical Research Course
Conducting Clinical Trials in an Academic Neurology Setting
- 2017 Clinical Trial Methodology Course, NINDS Invited Speaker
Biomarkers in Therapy Development Iowa City, IA
- 2017 Breaking Barriers for Young Women in Science/ Invited Speaker
Society for Neuroscience, Washington, DC
- 2018 ALS Clinical Therapeutic Pipeline/Invited Speaker
Walter Reed Neurology, Washington, DC
- 2018 Merlis Lecture/Invited Speaker

- University of Maryland, Baltimore, MD
- 2018 ALS Community Therapy Development Regulatory Pathways Workshop/Invited Panelist
- ALS Association, Washington, DC
- 2018 ALS Therapies: Present Status and the Pipeline/Invited Speaker
- 8th Annual Les Turner Symposium, Chicago, IL
- 2018 Collaborative Science to Accelerate Therapy Development for ALS/Invited Speaker
- 13th Annual Peggy and Gary Edwards Lecture, Houston, TX
- 2018 Amyotrophic Lateral Sclerosis /Invited Speaker
- Robert P. Lisak Event, Wayne State University, Detroit, MI
- 2019 Inaugural Neuroscience Symposium/Invited Speaker
- Holy Cross Hospital, Fort Lauderdale, FL
- 2019 Presentation of the Sheila Essay Award: An Award for ALS Research /Invited Speaker
- 2019 AAN Annual Meeting. Philadelphia, PA
- 2019 ALS Finding a Cure: Therapeutics Session Part IV: Brainstorming / Invited Speaker
- 2019 ALSFAC F2 Meeting, Stamford, CT
- 2019 Robert J. Adams Lecture: ALS Therapeutics 2019 – New Advances and Hope / Invited Speaker
- Medical University of South Carolina, Charleston, SC
- 2019 Brainstorming Neurodegeneration: Plenary – Accelerating CNS Therapy Development / Invited Speaker California Stem Cell Agency, San Francisco, CA
- 2019 Accelerating ALS Therapy Development: The First ALS Platform Trial / Invited Speaker. The ALS Association’s Sixth Annual Hope and Help Symposium, Orlando, FL
- 2019 Target ALS Annual Meeting: Master Platform Trials & The Healey Center for , ALS/Invited Speaker. Boston, MA
- 2019 Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases/Invited Speaker Gordon Research Conference, West Dover, VT
- 2019 American Neurological Association. Ray Adams Lectureship
- Accelerating ALS Trials: The First Platform Trial in ALS
- 2019 Clinical Trialists Path: Building Teams / Invited Speaker Society For Neuroscience Meet-the-Clinician-Expert Event, Chicago, Illinois
- 2019 18th Annual Northeast ALS Consortium Meeting – Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Northeast ALS Consortium, Clearwater Beach, Florida
- 2019 9th Annual ALS Clinical Research Learning Institute – The ALS Research Pipeline Clinical Research Learning Institute, Clearwater Beach, Florida
- 2019 144th Annual Meeting of the ANA – Optimizing Clinical Trial American Neurological Association, St. Louis, MO
- 2020 The Healey ALS Platform Trial - Accelerate Drug Development for ALS Through Innovative Trial Designs/ Grand Rounds
- University of Pennsylvania, Philadelphia, PA (Virtual)
- 2020 Reimaging ALS Trials – New Science, New Approaches Grand Rounds
- Stanford University Medical Center, Stanford, CA (Virtual)
- 2020 ALSFAC Fall Meeting Virtual - Healey ALS Platform Trial
- ALS Finding a Cure, Stamford, CT
- 2020 19th Annual Northeast ALS Consortium Virtual Meeting – The Healey Platform Trial
- Northeast ALS Consortium, Pasadena, CA 91105-1955

- 2020 19th Annual Northeast ALS Consortium Virtual Meeting – Exploratory Patient-Reported Outcomes in the Multiple Dose Study of Tofersen (BIIB067) in Participants with ALS
Northeast ALS Consortium, Virtual
- 2020 ANA Professional Development Workshop Virtual Meeting – Negotiations and Contracts
American Neurological Association
- 2020 AANEM 2020 Annual Virtual Meeting – ALS Therapeutics: New Treatments and
New Approaches
American Association of Neuromuscular & Electrodiagnostic Medicine
- 2020 48th Annual Robert B. Aird Professorship Virtual Webinar. New Insights and Approaches
for ALS Therapy Development. Oct 21st, 2020
Department of Neurology, University of California, San Francisco.
- 2020 10th Annual Gilden Lectureship. Virtual Invited Lecture. What’s New in ALS Therapeutics
November 11th, 2020. Dept of Neurology, University of Colorado School of Medicine
- 2020 7th International Symposium Virtual Meeting on Focused Ultrasound 2020 - Therapeutic
Advances in Neurodegenerative Disorders: ALS as an example. Invited/Keynote Speaker.
Focused Ultrasound Foundation.
- 2020 Clinical Research Forum 2020 IT Roundable. Virtual Meeting. Invited Speaker.
Accelerating Drug Development Through Innovative Trial Designs.
- 2020 Excitement and Progress in ALS Therapy Development/Invited Speaker
Takeda Science Virtual Forum
- 2020 ALS Therapy Development 2020/Invited Speaker Wave Science Virtual Forum
- 2020 ALS Therapeutic Updates/Invited Grand Round Speaker, NYU School of Medicine, Dept
of Neurology, Virtual Forum
- 2021 3rd Annual South Florida Neuroscience, HCH & ALS Patient Symposium
Breaking Update: ALS Clinical Trials
- 2021 Setting up for career success, Virtual NINDS R25/Invited Speaker
Office of Training and Workforce Development NINDS, NIH, Bethesda, MD
- 2021 Virtual Working Group Seminar - Starting New Collaborative Initiatives /Invited Speaker
University of Rochester Medical Center, Monroe County, NY.
- 2021 Michael McDermott Endowed Lectureship in Experimental Therapeutics Virtual /Grand
Rounds/Invited Speaker
University of Rochester Medical Center, Monroe County, NY.
- 2021 Ax-S Thursdays Series on Expanding Access to New Medicines Title – HEALEY ALS
Platform Trials Repurposing Studies, and Clinical Discoveries – accelerating progress and
access/Invited Speaker Ax-S Pharma San Francisco, CA.
- 2021 10th Annual Resident Research Day, virtual - New Therapies in ALS/ Invited Speaker
Department of Neurology, University of Miami, Miami, FL
- 2021 Virtual - Motor Neuron Disease/Amyotrophic Lateral Sclerosis - Determinants of clinical
response to levosimendan in the REFALS phase 3 study in people with ALS/ Invited
Speaker Annual Meeting: World’s Premier Neurology Meeting | AAN, Minneapolis, MN
- 2021 2nd Annual George Paulson Lectureship – New Therapies in ALS/Invited Speaker
Ohio State University, College of Medicine, Columbus, OH.
- 2021 ALS Finding A Cure - Session III: Healey ALS Platform Update, Answer ALS Update.
Virtual / Invited Speaker. ALS Finding A Cure, Stamford, CT.
- 2021 Tenth Annual Hope Center Retreat - New Therapies for ALS / Virtual / Invited Speaker
Hope Center for Neurological Disorders, St. Louis, MO
- 2021 The University of Chicago – New Therapeutics for ALS / Virtual / Invited Speaker
Neurology Grand Rounds University of Chicago, Chicago, IL
- 2021 Rush University, New Therapeutic Development for ALS / Virtual / Invited Speaker

2021 Neurology Grand Rounds Rush University Medical Center, Chicago, IL
ALSFAC Virtual Meeting - Healey ALS Platform Trial Update
ALS Finding a Cure, Stamford, CT

International

1995 Update on familial ALS/ Invited Speaker
American Congress of Neurology, Guatemala City, Guatemala

2001 Clinical trial of Minocycline in Huntington's Disease/ Invited Speaker
Huntington's Disease Study Group Annual Meeting, Toronto, Canada

2002 From bench to bedside and back: Therapies in ALS/ Invited Plenary Speaker
International Motor Neuron Disease Symposium, Melbourne, Australia

2002 Experimental therapies in ALS/ Invited Expert Panelist
Australia Motor Neuron Disease Society, Melbourne, Australia

2002 Clinical trial of Topiramate in ALS/ Invited Speaker (abstract)
International Motor Neuron Disease Symposium, Melbourne, Australia

2003 Dementia and ALS/Invited Speaker Expert Panel
Novartis Neuroscience Advisory Board Meeting, Seville, Spain

2004 Three invited presentations
Celebrex in ALS (abstract)
Ask the Experts Clinical Trials in ALS
Clinical Symposium highlights
International Motor Neuron Disease Symposium, Philadelphia

2006 ALS trials challenges and the future/ Invited Speaker
2nd Annula Symposium de al Fondation Andres-Delambre on ALS, Québec, Canada

2006 Phase IIA clinical trial of Arimoclomol in ALS (abstract)
International Motor Neuron Disease Symposium, Yokohama, Japan

2007 ALS lessons from past trials/ Invited Speaker
3rd Annual Symposium de al Fondation Andres-Delambre on ALS, Montréal, Canada

2007 Longitudinal metabolomic profiling in plasma from patients with ALS (abstract)
International Motor Neuron Disease Symposium, Toronto, Canada

2008 Advances in ALS Therapy, A Brave New World/ Invited Speaker

2009 4th Annual Symposium de al Fondation Andres-Delambre on ALS, Montréal, Canada
Two Presentations
Ceftriaxone in ALS: results of stages 1 and 2 (abstract)
KNS760704-CL-201, Part 1: a 12 week phase 2 study of the safety, tolerability and clinical effect in ALS subjects (abstract)
20th International Motor Neuron Symposium, Berlin Germany

2010 AAN Clinical trial research fellowship: Case study of success/ Two Presentations/
Invited Speaker
AAN/NINDS Research Career Development Symposium
A Phase 2 study of KNS760704 in ALS/ Invited Plenary Speaker
American Academy of Neurology Annual Meeting, Toronto, Canada

2010 More power to you: Impact of trial design on adherence and outcome/ Invited Plenary
Speaker
21st International Motor Neuron Symposium, Orlando

- 2010 Biobanks and Standard Operating Procedures for Biomarkers in ALS/ Invited Speaker
International Symposium on Biomarkers in ALS Ulm, Germany
- 2010 Present and future of ALS clinical research/ Invited Plenary Speaker
1st ARISLA Conference, Milan, Italy
- 2011 Update on ALS Therapies/ Invited Speaker
Suna Kirac Conferences on Neurodegeneration, Istanbul, Turkey
- 2012 ALS: Exploratory and Confirmatory Trials/ Invited Speaker
Symposium sur la SLA de la Fondation Andre-Delambre
Quebec
- 2013 Novel Approaches for the Treatment of Amyotrophic Lateral Sclerosis/ Invited Speaker
The International Conference on Alzheimer's & Parkinson's Diseases, Florence, Italy
- 2013 Academic Career and Family: Can you have it all?/
Mexican Academy of Neurology. Merida, Yucutan, Mexico
- 2013 Neuromuscular Diseases/NEALS
Mexican Academy of Neurology. Merida, Yucutan, Mexico
- 2014 Infrastructure of the trial: ALS registry in the US Northeast/ Invited Speaker
MAN/ANA Symposium. Cancun, Mexico
- 2016 ALS Trials and Trialists: New Opportunities and Approaches to Find Treatments for Our
Patients./ Invited Speaker
ENCALS Meeting 2016. Milan, Italy
- 2016 Challenges and Opportunities in ALS Clinical Trials/ Invited Speaker
4th Annual CTNI Europe Symposium. Stresa, Italy
- 2016 ALS SOD1 trials/ Invited Speaker
The Lancet Neurology Conference. London, United Kingdom
- 2016 Mexican Academy of Neurology Conference/ Invited Speaker
Pan American Congress of Neurology. Cancún, Mexico
- 2016 Neurofilaments in ALS clinics and beyond/ Invited Speaker
27th International Symposium on ALS/MND. Dublin, Ireland
- 2017 ALS - targeted treatments based on underlying biology. New science and new hope
Finland Centennial: Building the future together; Academic Medicine and Pharma
Academic Medical Center Helsinki/Invited Plenary Speaker
- 2017 The crisis we want: Are healthcare systems prepared for a disease modifying drug?
World Neuroscience Innovation Forum, London, UK/Panel Moderator
- 2017 ALS therapeutics and opportunities for collaboration. Invited Speaker
ALS Clinical and Basic Research in China and the United States Beijing, China
- 2018 Amyotrophic Lateral Sclerosis – Alagoas in Motion / Invited Speaker
First International Symposium. Maceió, Brazil
- 2019 Florey Institute of Neuroscience and Mental Health/ Invited Speaker
Fight MND. International Motor Neuron Disease Symposium. Melbourne, Australia
- 2019 Macquarie University and the Faculty of Medicine and Health Sciences/Invited Speaker
International Symposium. Sydney, Australia
- 2019 Accelerating ALS-treatment discovery: targets, therapies and platform trials. /Invited
Speaker. International Conference on Neurological Disorders and Neurorestoration.
Dubrovnik, Croatia
- 2019 Accelerating Therapy Development: Lesson From NeuroNEXT Phase II Network and
ALS/ Invited Speaker
14th International Conference in Alzheimer's & Parkinson's Diseases. Lisbon, Portugal
- 2019 Master Platform Trial: Invited Speaker. Symposium sur la SLA de la Fondation Andre-
Delambre, Montreal, Canada

- 2019 New Therapeutic Approaches to ALS. /Invited Speaker. VII Annual Symposium.
Rome, Italy
- 2020 ALS Platform Trial Initiative: Accelerating Therapy Development. /Invited Speaker
AAT-AD/PD 2020. Virtual Lecture, Vienna, Austria
- 2020 ALS Therapies – Therapies in Late Stage Testing Therapeutic Pipeline Healey ALS
Platform Trial / Virtual Grand Rounds
University of Alberta, Edmonton, Alberta, Canada
- 2020 The Refals Phase 3 Study of Levosimendan in Patients with ALS
31st International Symposium on ALS/MND – Virtual Lecture
- 2020 NurOwn ALS Phase 3 Clinical Trial Update
31st International Symposium on ALS/MND – Virtual Lecture
- 2020 Healey ALS Platform Trial Canadian ALS Network, Virtual Lecture
- 2021 III International Symposium on Amyotrophic Lateral Sclerosis – Virtual/Invited Speaker
International Symposium, Brazil
- 2021 III Congreso SOLANE 2021, Latin American Society for Neuromuscular Diseases –
Virtual/Invited Speaker
International Symposium, Chile
- 2021 PACTALS 2021 Nagoya Symposium, Hot Topics of Clinical Trials for ALS / Virtual /
Invited Keynote Speaker
Aichi Medical University, Yazakokarimata, Nagakute, Aichi, Japan
- 2021 PACTALS 2021 Nagoya Symposium, Current Progress of Therapeutic Development for
ALS / Virtual / Invited Speaker
Aichi Medical University, Yazakokarimata, Nagakute, Aichi, Japan

Report of Clinical Activities and Innovations

Current Licensure and Certification

1995 Massachusetts Medical License

Practice Activities

1996-2004	Ambulatory Care	Huntington’s Disease Clinic, MGH	Two sessions a month
1996- 1998- 2009	Ambulatory Care Inpatient attending	ALS Clinic, MGH Neurology Service, MGH	One session a week One month a year
2007-11	Inpatient attending	Neurology Service, MGH	Two weeks a year

Clinical Innovations

New England Telemedicine Care Program: ALS telemedicine collaborative started in late 2010 to improve access to care and clinical research for people with amyotrophic lateral sclerosis living in New England.

ALS ONE program: Hospitals in MA coordinate care of patients with ALS

ALS House call program

ALS parenting at a challenging time program

Expanded Access Program

Report of Technological and Other Scientific Innovations

Biomarker assay for ALS	US patent 11/711,518, filed 2/27/07; and International Patent Application No. PCT/US2007/004998 filed on 2/27/07. Cudkowicz ME, Brown RH and staff from Metabolon, inventors. Biomarkers for Amyotrophic lateral Sclerosis and Methods Using the Same The present invention provides various biomarkers of amyotrophic lateral sclerosis (ALS) as well as providing various methods of using the biomarkers. Methods for biomarker usage include diagnosis, determining predisposition, monitoring progression/regression, assessing efficacy of compositions for treating ALS, screening compositions for activity in modulating biomarkers of ALS, treating ALS, as well as other methods based on biomarkers of ALS.
ATLIS – an apparatus to quantitatively measure strength	US patent 11-715200, filed 3/7/07. Andres P, Cudkowicz ME, MGH inventors. Isometric Strength Testing Apparatus. Accurate Test of Limb Isometric Strength (ATLIS) was designed to be portable, quick, and easy to use device measuring isometric strength. This device could more precisely measure whether an experimental drug slows the progression of ALS or other neuromuscular diseases, allowing more drugs to be tested quicker and at less expense.
Role of Microglia in Retinitis Pigmentosa	NIH R01EY027921 (PI: Weiner HL, /Co-PI: Butovsky O, Cudkowicz ME. The focus of this grant proposal is to characterize retinal microglia and how they regulate and/or participate in retinal damage in both animal models of retinitis pigmentosa and in eyes from human subjects. We will investigate whether retinitis pigmentosa in animal models can be treated by specifically targeting and modulating microglia. We will use new technology and approaches to understand features of microglia cells that can then be exploited to develop novel microglia-targeting therapies to treat humans with retinitis pigmentosa.
Randomized, Double-Blind, Placebo-Controlled Trial of Arimoclomol in Rapidly Progressive SOD1 ALS	MGH Invention 25521 (PI: Cudkowicz, ME, Co-PI Atassi N, Schoenfeld D. The clinical trial was funded by the FDA and was joint initiative with Dr Micheal Benetar. Dr. Cudkowicz led the first trials of Arimoclomol in ALS. This was a study just in people with rapidly progressive SOD1 ALS.

Report of Education of Patients and Service to the Community

Activities

- 1999 Therapeutic strategies in ALS/ Invited Speaker
New York ALS Association Symposium, New York City
- 1999 Therapeutic advances in ALS/ Invited Speaker
Rhode Island ALS Association Symposium, Providence
- 2001 ALS clinical research update/ Invited Speaker
ALS Hope Foundation, Philadelphia
- 2003 Updates in the new millennium/ Invited Speaker
ALS Association of New Hampshire, Portsmouth
- 2003 Therapeutic advances in ALS/Invited Speaker
Muscular Dystrophy Association of Rhode Island, Pawtucket
- 2005 Therapies for ALS Update/ Invited Speaker
ALS Association New York Chapter, New York City
- 2006 ALS Updates: Genes, mechanisms and therapies/ Invited Speaker
Rhode Island ALS Association Symposium, Providence
- 2010 ALS Treatments and Hopes: Roadmap to the Cure/ Invited Speaker
ALS Association May Advocacy Day, Washington
- 2010 ALS Therapeutics, a time for hope/ Invited Speaker
ALS Therapy Development Foundation Research Day, Cambridge
- 2010 Therapeutics in 2010/ Invited Speaker
ALS Association Ask the Experts, Orlando
- 2011 Multidisciplinary Care and Therapeutic Advances for People with ALS/ Invited
Speaker
Scholarship in Medicine Distinguished Speaker Series, Maine General Medical
Center,
Waterville
- 2011 Annual Leadership Summit/ Invited Speaker
ALS Therapy Development Institute, Cambridge
- 2013 The Northeast ALS Consortium
ALS Clinical Trials: Pipeline Update Summer 2013
- 2014 MGH ALS Program: drugs, genes, stem cells: therapeutic revolution
- 2014 The Northeast ALS Consortium
Drugs, gene therapy, stem cells: Therapeutic revolution in ALS
- 2015 The Northeast ALS Consortium
The ALS Research Pipeline
- 2016 ALS Association National: ALS Advocacy Day & Public Policy Conference/ Invited
Speaker
Current trials, stem cell trials, Retigabine and ALS ACT
- 2017 Status of ALS therapies/Invited Speaker
Florida ALS Association patient event
- 2018 ALS Therapy Update/Invited Speaker
Bonita Springs, FL patient event
- 2020 The McCourt Foundation Education Update/Invited Speaker
Innovations for a Cure: Clinical & Research Advances in ALS

2020	ALS Roundtable tele series/Invited Speaker What's New in ALS Therapy Development ALS Association Greater Chicago Chapter, Chicago, IL (Virtual)
2020	Argentina video-conference for ALS Community/Invited Speaker ALS Therapies 2020 ASOCIACION ELA ARGENTINA, Buenos Aires, Argentina
2020	Webinar on Innovation in Trial Design: Bringing together a community to innovate the ALS clinical trial landscape. International MND Alliance.
2020	NEALS Patient Webinar on the REFALS Phase 3 Study of Levosimendan in ALS. 12/5/2020
2020	10 th Annual ALS Clinical Research Learning Institute Virtual Meeting – The ALS Research Pipeline. Clinical Research Learning Institute, Virtual
2021	ALS Drug Development Webinar Series Part 6: Patient Engagement in Clinical Trials Virtual Meeting.

Educational Material for Patients and the Lay Community

Books, monographs, articles and presentations in other media

2008	ALS diagnosis, clinical care and clinical research video	Lecturer for a videotaped series utilized as a training tool to establish ALS centers in China
2010	Clinical Trials 101 and Ceftriaxone Clinical Trials	Lecturer in a webinar for patients with ALS
2011	The effects of dexamipexole (KNS- 760704) in individuals with amyotrophic lateral sclerosis	Speaker for a Nature Medicine, podcast http://www.nature.com/nm/podcast/index.html

Educational material or curricula developed for non-professional students

2011	ALS Trial Update	Lecturer in a webinar, ALS Therapy Development Institute
------	------------------	---

Recognition

2007	Medical All Star Awardee	Boston Red Sox
2007, 2013-2016	Top Doctors	Boston Magazine
2019	Top Doctors	Boston Magazine
2020	Top Doctors	Boston Magazine

Report of Scholarship

Peer reviewed publications in print or other media

Research Investigations

1. **Cudkowicz ME**, de la Monte SM. Histogenesis and cell lineage analysis of medulloblastomas. *Journal Neurology Science*. 1989; 94(1-3):221-229.
2. **Cudkowicz ME**, Kowall NW. Degeneration of pyramidal projection neurons in Huntington's disease cortex. *Annals Neurology*. 1990; 27(2):200-204.
3. Hausdorff JM, Mitchell SL, Firtion R, Peng CK, **Cudkowicz ME**, Wei JY, Goldberger AL. Altered Fractal Dynamics of Gait: Reduced Stride Interval Correlations with Aging and Huntington's Disease. *Journal of Applied Physiology* 1997; 82(1):262-269.
4. **Cudkowicz ME**, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden D, Horvitz HR, Brown RH. Epidemiology of SOD1 Mutations in Amyotrophic Lateral Sclerosis. *Annals Neurology*. 1997; 41(2):210-221.
5. **Cudkowicz ME**, Warren L, Francis JW, Lloyd K, Friedlander R, Borges LM, Kassem N, Munsat TL, Brown RH. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: A preliminary safety and pharmacokinetic study. *Neurology*. 1997; 49(1):213-222.
6. Hausdorff JM, **Cudkowicz ME**, Firtion R, Wei JY, Goldberger AL. Gait variability and basal ganglia disorders: Stride-to stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. *Movement Disorders*. 1998; 13(3):428-437.
7. **Cudkowicz ME**, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH. Limited corticospinal tract involvement in amyotrophic lateral sclerosis. *Annals Neurology*. 1998; 43(6):703-710.
8. **Cudkowicz ME**, Sexton PM, Ellis T, Hayden DL, Gwilt PR, Li X-Y, Whalen J, Brown RH. The Pharmacokinetics and Pharmacodynamics of Procyistine® (L-2-oxothiazolidine-4-carboxylic acid) Treatment in Subjects with Amyotrophic Lateral Sclerosis (ALS). *Neurology* 1999; 52(7):1492-1494.
9. Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, **Cudkowicz ME**. Riluzole therapy in Huntington's Disease. *Movement Disorders* 1999; 14(2):336-340.

10. Montine TJ, Beal FM, **Cudkowicz ME**, Brown RH, O'Donnell H, Margolin R, Robert LJ, Morrow JD. Increased CSF F2-Isoprostane concentration in probable Alzheimer's Disease. *Neurology*. 1999; 52(3):562-565.
11. Upton-Rice MN, **Cudkowicz ME**, Mathew RK, Reif D, Brown RH. Administration of NOS inhibitors do not alter disease course of ALS SOD1 mutant transgenic mice. *Annals Neurology*. 1999; 45(3):413-414.
12. Montine TJ, Beal MF, Robertson D, **Cudkowicz ME**, Biaggoni I, O'Donnell H, Zackert WE, Roberts LJ, Morrow JD. Cerebrospinal Fluid F2-isoprostanes are elevated in Huntington's disease. *Neurology*. 1999; 52(5):1104-1105.
13. Upton-Rice MN, **Cudkowicz ME**, Warren L, Mathew RK, Ren JM, Finkelstein SP, Brown RH. Basic fibroblast growth factor does not prolong survival in a transgenic model of familial ALS. *Annals Neurology*. 1999; 46(6):934.
14. Marder K, Ahao H, Myers RH, **Cudkowicz ME**, Kayson E, Kieburz K, Orme C, Paulsen J, Penney J, Siemers E, Shoulson I, and the Huntington Study Group. Rate of Functional decline in Huntington's Disease. *Neurology*. 2000; 54(2):452-458.
15. Ellis T, **Cudkowicz ME**, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's Disease. *J Neuropsychiatry* 2000; 12(3):364-369.
16. Bogdanov M, Brown RH, Matson W, Hayden D, O'Donnell H, Beal F, **Cudkowicz ME**. Increased oxidative damage to DNA in ALS patients. *Free Radical Biology and Medicine*. 2000; 29(7):652-658.
17. Hausdorff JM, Lertratanakul A, **Cudkowicz ME**, Peterson AL, Kaliton D, Goldberger AL. Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. *Journal Applied Physiology*. 2000; 88(6):2045-2053.
18. Shefner JM, Brown RH, Cole D, Chaturvedi P, Ogenstad S, Pastuszak K, Matthews R, Upton-Rice M, **Cudkowicz ME**. Effect of Neurophilin Ligands on Motor Units in Mice with SOD1 ALS Mutations. *Neurology* 2001; 57(10):1857-1861.
19. Mandler RN, Anderson FA, Miller RG, Clawson L, **Cudkowicz ME**, Del Bene M, and the ALS Care Study Group. The ALS patient care database: Insights into end of life care in ALS. *Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*. 2001;2(4):203-208.
20. Shefner JM, **Cudkowicz ME**, Brown RH. Comparison of incremental with multipoint MUNE methods in transgenic ALS mice. *Muscle and Nerve* 2002;25(1):39-42.
21. Dreibelbis J, Brown RH, Pastusza K, Kaplan P, **Cudkowicz ME**. Disease course unaltered by a single intracisternal injection of BMP-7 in ALS mice. *Muscle and Nerve*. 2002; 25(1):122-123.

22. Cudkowicz ME, Pastusza KA, Sapp PC, Mathews RK, Leahy J, Pasinelli P, Francis JW, Jiang D, Andersen JK, Brown RH. Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity. *Neurology*. 2002; 59(5):729-734.
23. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel, M, **Cudkowicz ME**, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG and Goldstein JM. Evidence of more widespread cerebral pathology in early HD: An MRI based morphometric analysis. *Neurology*. 2003; 60(10):1615-1619.
24. Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, **Cudkowicz ME**, Beal MF. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative disorders. *Journal of the Neurological Sciences*. 2003; 207(1-2):71-76.
25. Al-Chalabi A, Scheffler MD, Smith BN, Parton MJ, **Cudkowicz ME**, Andersen PM, Hayden DL, Hansen VK, Turner, MR, Shaw, CE, Leigh PN, Brown RH Jr. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. *Annals Neurology*. 2003; 54(1):130-134.
26. **Cudkowicz ME**, Shefner JM, Schoenfeld D, Brown RH, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, MD, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Goldstein J, Hulihan J and the Northeast ALS Consortium. A randomized, placebo- controlled trial of Topiramate in amyotrophic lateral sclerosis. *Neurology*. 2003; 61(4):456-464.
27. Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, **Cudkowicz ME**, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. *Neurochemistry International* 2003; 43(3);191-196.
28. Gajewski CD, Lin MT, **Cudkowicz ME**, Beal MF, Manfredi G. Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho (O) cells. *Experimental Neurology*. 2003; 179(2);229-235.
29. Traynor B, Zhang H, Shefner J, Schoenfeld D, **Cudkowicz ME**. Functional outcome measures as clinical trial endpoints in Amyotrophic Lateral Sclerosis. *Neurology*. 2004; 63(10): 1933–1935
30. Shefner JM, **Cudkowicz ME**, Schoenfeld D, et al. A clinical trial of Creatine in amyotrophic lateral sclerosis. *Neurology*. 2004; 63(9):1656-1661
31. Shefner JM, **Cudkowicz ME**, Zhang H. The use of statistical MUNE in a multicenter ALS clinical trial. *Muscle and Nerve*. 2004; 30(4):463-469.
32. Weisskopf MG, McCullough ML, Calle EE, Thun MJ, **Cudkowicz ME**, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. *American Journal of Epidemiology*. 2004; 160(1);26-33.

33. Ascherio A, Weisskopf MG, O'Reilly EJ, Jacobs EJ, McCullough ML, Calle EE, **Cudkowicz ME**, Thun MJ. Vitamin E intake and risk of amyotrophic lateral sclerosis. *Annals of Neurology*. 2005; 57(1):104-110.
34. Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Thun MJ, **Cudkowicz ME**, Ascherio A. Prospective study of military service and mortality from amyotrophic lateral sclerosis. *Neurology*. 2005; 64(1):32-37.
35. Steele AJ, Al-Chalabi A, Ferrante KM, **Cudkowicz ME**, Brown RH, Garson JA. Detection of Serum Reverse Transcriptase Activity in ALS Patients and Unaffected Blood Relatives. *Neurology*. 2005; 64(3):454-45.
36. Ryu H, Smith K, Camelo SI, Carreras I, Junghee L, Iglesias AH, Dangond F, Cormier KA, **Cudkowicz ME**, Brown RH, Ferrante RJ. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic mice. *Journal of Neurochemistry*. 2005; 93(5):1087-1098.
37. Rozen S, **Cudkowicz ME***, Bogdanov M, et al. Metabolomic analysis and signatures in motor neuron disease. *Metabolomics* 2005; 1(2):101-108 (*co-first authors)
38. Ferrante KL, Shefner J, Zhang H, Betensky R, Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, **Cudkowicz ME**. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. *Neurology*. 2005; 65(11):1834-1836.
39. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, **Cudkowicz ME**, Brown RH Jr, Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. *J Neurochem*. 2005; 95(5):1461-71.
40. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, **Cudkowicz ME**, Friedlander RM, Ferrante RJ. Combination Therapy Using Minocycline and Coenzyme Q10 in R6/2 Transgenic HD Mice. *Biochimica et Biophysica Acta*. 2006; 1762(3):373-80.
41. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, **Cudkowicz ME**, Newhall K, Peskind E, Marcus S, Ho L. Identification of potential CSF biomarkers in ALS. *Neurology*. 2006; 66(8):1218-1222.
42. Qureshi M, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, Hilgenberg S, Smart R, Brown R, **Cudkowicz ME**. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). *Amyotrophic Lateral Sclerosis and other motor neuron disorders*. 2006; 7(3):173-182.
43. Shefner JM, **Cudkowicz ME**, Brown RH Jr. Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. *Muscle Nerve*. 2006; 34(5):603-607.

44. Traynor B, Bruijn L, Conwit RA, Beal F, O'Neill G, Fagan S **Cudkowicz ME**. Neuroprotective agents for clinical trials in ALS: A systematic assessment. *Neurology*. 2006; 67(1):20-27.
45. **Cudkowicz ME**, Shefner JM, Schoenfeld DA et al. Trial of Celecoxib in Amyotrophic Lateral Sclerosis. *Annals of Neurology*. 2006; 60(1):22-31.
46. Vucic S, Tian D, Siao Tick Chong P, **Cudkowicz ME**, Hedley-Whyte ET, Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): A novel syndrome in neurology. *Brain*. 2006; 129(12):3384-90.
47. Shefner JM, **Cudkowicz ME**, Zhang H, Schoenfeld D, Jilapalli D, and the Northeast ALS Consortium. Revised statistical MUNE in the Celecoxib/ALS Trial. *Muscle and Nerve*. 2007; 35(2):228-34.
48. Qureshi MM, **Cudkowicz ME**, Zhang H, Raynor E. Increased incidence of deep venous thrombosis in ALS. *Neurology*. 2007; 68(1):76-77.
49. Miller R, Bradley W, **Cudkowicz ME**, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann, H, Sauer D, Silani V, Strong M, Swash M, Vernotica, E and The TCH 346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. *Neurology*. 2007; 69(8):776-784.
50. Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH, **Cudkowicz ME**, Gordon PH, Hardy J, et al for the ALS Research Group. Amyotrophic lateral sclerosis: An emerging era of collaborative gene discovery. *PloS ONE*. 2007; 2(12):e1254.
51. Rutkove SB, Zhang H, Schoenfeld DA, Raynor EM, Shefnerj JM, **Cudkowicz ME**, Chin AB, Aaron R, Schiffman CA. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. *Clinical Neurophysiology*. 2007; 118(11):2413-2418.
52. McCormick AL, Brown RH, **Cudkowicz ME**, Al Chalabi A, Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. *Neurology*. 2008; 70(4):278-283.
53. Caraganis A, Benn S, **Cudkowicz ME**, Brown RH. Thrombopoietin is ineffective in a mouse model of motor neuron disease. *Amyotroph Lateral Scler* 2008; 9(6):354-548.
54. Wills AM, Landers JE, Zhang H, Richter RJ, Caraganis AJ, **Cudkowicz ME**, Furlong CE, Brown RH Jr. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. *Neurology*. 2008; 70(12):929-934.
55. **Cudkowicz ME**, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR and the Northeast ALS Consortium. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in ALS. *Muscle and Nerve*. 2008; 38 (1):837-844.
56. Qureshi M, Shui A, DiBernardo AB, Brown RH, Schoenfeld DA, **Cudkowicz ME**. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2008; 9(6):369-374.

57. Bedlack RS, Pastula D, Welch E, Pulley D, **Cudkowicz ME**. Scrutinizing Enrollment in ALS Clinical Trials. *Amyotroph Lateral Scler* 2008; 9(5):257-65.
58. Qureshi M, Brown RH, Rogers JT, **Cudkowicz ME**. Ferritin levels and metals as risk factors in amyotrophic lateral sclerosis. *Open Neurology Journal*. 2008; 2:51-54.
59. Del Signore S, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, Smith K, **Cudkowicz ME**, Ferrante RJ. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. *Amyotrophic Lateral Sclerosis* 2009; 10(2):85-94.
60. **Cudkowicz ME**, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante FJ. Phase 2 study of sodium phenylbutyrate in ALS. *Amyotrophic Lateral Sclerosis*. 2009; 10 (2):99-106.
61. Gordon PH, Corcia P, Lacomblez L, Pochigaeva K, Abitbol J-P, **Cudkowicz ME**, Nigel PN, Meininger V. Defining Survival as an Outcome Measure in ALS. *Archives of Neurology* 2009; 66(6):758-761.
62. Qureshi M, Schoenfeld D, Paliwal Y, Shui A, **Cudkowicz ME**. The natural history of ALS is changing; improved survival. *Amyotrophic Lateral Sclerosis*. 2009; 10(5-6):324-331.
63. Qureshi M, Bedlack RS, **Cudkowicz ME**. Lyme disease serology in amyotrophic lateral sclerosis. *Muscle and Nerve* 2009; 40(4):626-630.
64. Harel NY, **Cudkowicz ME**, Brown RH, Strittmatter SM. Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients. *Biomarkers* 2009; 14 (6): 414-417.
65. Castrillo C, Grasso D, Simpson E, Shefner J, **Cudkowicz ME**. Clinical significance of change in ALSFRS-R. *Amyotrophic Lateral Sclerosis*. 2010; 11(1-2):178-180.
66. Ryberg H, An J, Darko S, Lustgarten JL, Gopalakrishnan V, Lacomis D, **Cudkowicz ME**, Bowser R. Discovery and Verification of Amyotrophic Lateral Sclerosis Biomarkers by Proteomics. *Muscle and Nerve*. 2010; 42(1): 104–111.
67. Aggarwal S, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Conwit RA, Schoenfeld D, Shefner J, **Cudkowicz ME** and the Northeast ALS (NEALS) and Canadian ALS (CALs), Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurology*. 2010; 9(5):481-488.
68. Atassi A, Ratai EM, Greenblatt DJ, Pulley D, Zhao J, Bombardier J, Wallace S, Eckendrode J, **Cudkowicz ME**, DiBernardo A. A Phase 1, Pharmacokinetic, Dosage-Escalation Study of Creatine Monohydrate in Subjects with Amyotrophic Lateral Sclerosis. *Amyotrophic Lateral Sclerosis*. 2010; 11(6):508-13.
69. Zhou JY, Afjehi-Sadat L, Asress S, Duong DM, **Cudkowicz ME**, Glass JD, Peng J. Galectin-3 Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis: Discovery by a Proteomics Approach. *Journal of Proteome Research*. 2010; 9(10):5133-5141.

70. Huntington Study Group Pre2CARE Investigators, Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Bleeck EA, **Cudkowicz ME**, Ferrante RJ, Como P, Frank S, Zimmerman C, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, Metakis LJ. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. *Movement Disorders*. 2010; 25(12):1924-1928.
71. Royce-Nagel G, **Cudkowicz ME**, Myers D, Nicholson K, Shui A, Schoenfeld D, Huang X, Brown RH. Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*. 2010; 11(5):492-493.
72. Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, **Cudkowicz ME**. Depression in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*. 2011; 12(2):109-112.
73. Sherman A, Bowser R, Grasso D, Power B, Milligan C, Jaffa M, **Cudkowicz ME**. Proposed BioRepository platform solution for the ALS research community. *Amyotrophic Lateral Sclerosis*. 2011; 12(1):11-16.
74. Nefussy B, Hirsch J, **Cudkowicz ME**, Drory VE. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. *Journal of Neurological Sciences*. 2011; 300(1-2):23-27.
75. Paganoni S, Deng J, Jaffa M, **Cudkowicz ME**, Willis AM. Body Mass Index, not dyslipidemia, is an independent predictor of survival in ALS. *Muscle and Nerve*. 2011; 44(1):20-24.
76. Van Blitterswijk M, Gulati S, Smooth E, Jaffa M, Maher N, Hyman B, Ivinson A, Scherzer C, Schoenfeld D, **Cudkowicz ME**, Brown R, Bosco D. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*. 2011; 12(6):430-438.
77. **Cudkowicz ME**, Bozik M, Ingersoll E, Miller R, Mitsumoto H, Shefner J, Moore D, Schoenfeld D, Mather J, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff V. The effects of dextrampipexole (KNS-76074) in patients with amyotrophic lateral sclerosis. *Nature Medicine*. 2011; 17(12):1652-1656.
78. Atassi N, **Cudkowicz ME**, Schoenfeld DA. Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler*. 2011;12(4):272-7.
79. Lawton KA, **Cudkowicz ME**, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn M, Ryals JA, Berry J. Biochemical Alterations Associated with ALS. *Amyotrophic Lateral Sclerosis*. 2012; 13(1):110-880.
80. Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, **Cudkowicz ME**. Validation of a New Strength Measurement Device for ALS Clinical Trials. *Muscle and Nerve*. 2012; 45(1): 81-85.

81. Yerramilli-Rao P, Beal MF, Watanabe D, Kieburz K, de Blicke EA, Kitano M, Hosoe K, Funahashi I, **Cudkowitz ME**. Oral Repeated Dose Toxicity Studies of Coenzyme Q10 in Beagle Dogs. *International Journal of Toxicology*. 2012; 31(1): 58-69.
82. Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, Costa J, **Cudkowitz ME**, Glass J, Jahn O, Lehnert S, Malaspina A, Parnetti L, Petzold A, Shaw P, Sherman A, Steinacker P, Süßmuth S, Teunissen C, Tumani H, Wuolikainen A, Ludolph A. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. *Amyotrophic Lateral Sclerosis*. 2012; 13(1):1-10.
83. Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman S, Kamel F, Nelson L, Topol B, Van Den Eeden S, Tanner C, **Cudkowitz ME**, Grasso D, Lawson R, Muralidhar S, Oddone E, Schmidt S, Hauser M. A high-density genome-wide association screen of sporadic ALS in US veterans. *PLoS ONE*. 2012; 7(3)e32768.
84. Paganoni S, Zhang M, Quiroz Zárata A, Jaffa M, Yu H, **Cudkowitz ME**, Wills AM. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. *Journal of Neurology*. 2012; 259(9):1923-1928.
85. Shefner J, Cedarbaum J, **Cudkowitz ME**, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell A. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in Amyotrophic Lateral Sclerosis. *Amyotrophic Lateral Sclerosis*. 2012; 13(5):430-438.
86. Butovsky O, Siddiqui S, Gabriely G, Lanser A, Dake B, Gopal M, Doykan C, Wu P, Reddy G, Iyer L, Lawson R, Berry JD, Krichevsky A, **Cudkowitz ME** and Weiner H. Modulation of inflammatory monocytes with a unique microRNA-gene signature ameliorates ALS in a mouse model. *Journal of Clinical Investigation*. 2012; 122(9):3063-3087.
87. Andres PL, English R, Mendoza M, Florence J, Malkus E, Schierbecker J, Siener C, Malspeis S, Schoenfeld DA, Munsat TL and **Cudkowitz ME**. Developing normalized strength scores for neuromuscular research. *Muscle Nerve*. 2013; 47(2):177–182.
88. Rudnicki S, Berry J, Ingersoll E, Archibald D, **Cudkowitz ME**, Kerr D, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2013; 14(1):44-51.
89. Cohen-Adad J, Zhao W, Keil B, Ratai EM, Triantafyllou C, Lawson R, Dheel C, Wald L, Rosen B, **Cudkowitz ME**, Atassi N. 7T MRI of the spinal cord can detect lateral corticospinal tract abnormality in ALS. *Muscle and Nerve* 2013;47(5):760-2.
90. Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman D, Wancewicz E, Bennett CF, Bowser R, **Cudkowitz ME**, Miller T. SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy. *Archives of Neurology*. 2012; 70(2):1-7.

91. Berry J, Miller R, **Cudkowicz ME**, Van Den Berg L, Kerr D, Ingersoll E, Archibald D. The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal. 2013; 14(3):162-168.
92. Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezanian K, Rothstein J, Greenblatt DJ, and **Cudkowicz ME** for the Northeast ALS Consortium Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis. PLoS ONE. 2013; 8(4);e61177.
93. Miller T, Pestronk A, David W, Rothstein J, Simpson E, Appel S, Andres P, Mahoney K, Allred P, Alexander K, Ostrow L, Schoenfeld D, Macklin E, Norris D, Manousakis G, Crisp M, Smith R, Bennett C, Bishop K, **Cudkowicz ME**. An antisense oligonucleotide against *SOD1* delivered intrathecally for patients with *SOD1* familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. The Lancet Neurology. 2013; 12(5):435-442.
94. Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, Deng J, Levine-Weinberg M, Shapiro J, Lee A, Joseph L, Macklin E, **Cudkowicz ME**. Analysis of Start-Up, Retention and Adherence in ALS Clinical Trials. Journal of Neurology. 2013;81(15):1350-1355.
95. Quinn C, Macklin E, Atassi N, Bowser R, Boylan K, **Cudkowicz ME**, Fournier C, Ladha SS, Lacomis D, Berry J. Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration. 2013; 14 (7-8):632-634.
96. **Cudkowicz ME**, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology. 2013;12(11):1059-1067.
97. Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G, Berry JD, Brown RH, **Cudkowicz ME**, Bean BP, Eggan K, Woolf CJ. Intrinsic membrane hyperexcitability of ALS patient-derived motor neurons. Cell Reports. 2014; 7(1):1-11.
98. The Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, **Cudkowicz ME**, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology. 2014; 71(2):141-150.
99. Zhao Y, **Cudkowicz ME**, Shefner JM, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezanian K, Harmatz JS, Schoenfeld D, Greenblatt DJ. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous

ceftriaxone in patients with amyotrophic lateral sclerosis. *Journal of Clinical Pharmacology*. 2014; 54(10):1180-1187.

100. Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, **Cudkowitz ME**. MDA Clinical Research Network. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet*. 2014; 383(9934):2065-2072.
101. Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawon R, Jaffa M, Milburn MV, Ryals JA, Bowser R, **Cudkowitz ME**, Berry JD; On behalf of the Northeast ALS Consortium. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2014; 15(5-6):362-70.
102. Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, **Cudkowitz ME**, Atassi N. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2014; 15(5-6):453-456.
103. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, **Cudkowitz ME** Leitner M. The PRO-ACT database: Design, initial analyses, and predictive features. *Neurology*. 2014; 83(19):1719-1725.
104. **Cudkowitz ME**, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt D, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolkoff-Rubin N, Zinman L, Shefner JM for the Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomized, double blind, placebo-controlled study. *Lancet Neurology*. 2014; 13(11):1083-1091.
105. Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh SY, Todd PK, Berry JD, **Cudkowitz ME**, Boeve BF, Dickson D, Floeter MK, Traynor BJ, Morelli C, Ratti A, Silani V, Rademakers R, Brown RH, Rothstein JD, Boylan KB, Petrucelli L, Disney MD. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. *Neuron*. 2014; 83(5):1043-1050.
106. Andrews JA, Paganoni S, Braastad C, **Cudkowitz M**, Atassi N. Disease burden in upper motor neuron syndromes: a survey of patient perspectives. *Journal of Clinical Neuromuscular Disease*. 2014; 16(2):104-105.
107. Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, **Cudkowitz ME**, van den Berg LH, Mather J, Petzinger T, Archibald D. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2014; 15(5-6):406-413.

108. McElhiney M, Rabkin JG, Goetz R, Katz J, Miller RG, Forshaw DA, David W, **Cudkowicz M**, Glass JD, Appel S, Simpson E, Mitsumoto H. Seeking a measure of clinically meaningful change in ALS. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2014; 15(7-8):398-405.
109. Meininger V, Pradat PF, Corse A, Al-Sarraj S, Brooks B, Caress JB, **Cudkowicz ME**, Kolg SJ, Lange D, Leigh PN, Meyer T, Milleri S, Morrison KE, Orrell RW, Peters G, Rothstein JD, Shefner J, Lavrov A, Williams N, Overend P, Price J, Bates S, Bullman J, Krull D, Berges A, Abila B, Meno-Tetang G, Wurthner J. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in ALS: a randomized, first in human clinical trial. *PLoS ONE*. 2014; 9(5):e97803.
110. Kuffner R, Zach N, Norels R, Hawe J, Schoenfeld D, Wang L, Li G, Fang L, Mackeys L, Hardiman O, **Cudkowicz ME**, Sherman A, Ertaylan G, Grosse M, Hothorn T, Van Ligenberg J, Macker JH, Meyer T, Scholkopf B, Tran L, Vaughan R, Stolovitzky G, Leitner M. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis. *Nature Biotechnology*. 2015; 33(1):51-57.
111. Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, **Cudkowicz ME**, Atassi N, Hooker JK (Corresponding Author). Increased in vivo Glial Activation in Patients with Amyotrophic Lateral Sclerosis: assessed with [11C]-PBR28. *NeuroImage: Clinical*. 2015; 19(7):409-414.
112. Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, Walker J, Sinani E, Katsovskiy I, **Cudkowicz ME**, Leitner ML. Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS? *Neurotherapeutics*. 2015; 12(2):417-423.
113. Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, Maragakis N, Schoenfeld D, Yu H, Atassi N, **Cudkowicz ME**, Miller TM. Pre-morbid type 2 diabetes mellitus is not a prognostic factor in ALS. *Muscle & Nerve*. 2015; 52(3):339-343.
114. Klein MM, Treister R, Raii T, Pascual-Leone A, Park L, Nurmikko T, Lenz F, Lefaucheur JP, Lang M, Hallett M, Fox M, Costello A, **Cudkowicz ME**, Carr DB, Ayache SS, Oaklander AL. Transcranial Magnetic Stimulation (TMS) of the Brain: Guidelines for Pain Treatment Research. *PAIN*. 2015; 156(9):1601-1614.
115. Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, **Cudkowicz ME**. Preclinical rodent toxicity studies for long term use of ceftriaxone. *Toxicology Report*. 2015; 2:1396-1403.
116. Weisskopf MG, **Cudkowicz ME**, Johnson N. Military Service and Amyotrophic Lateral Sclerosis in a Population-based Cohort. *Epidemiology*. 2015; 26(6):831-838.
117. Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, **Cudkowicz M**, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A and Phase 2 trial Np001 investigators. Randomized phase 2 trial of NP001- a novel immune regulator: Safety and early efficacy in ALS. *Neurology Neuroimmunology & Neuroinflammation*. 2015; 2(3):e100.
118. Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Soykan CE, Kiner O, Lawson RJ, Frosch MP, Pochet N, Fatimy RE, Krichevsky AM, Gygi SP, Lassmann H, Berry J, **Cudkowicz ME**, Weiner HL. Targeting miR-155 restores abnormal microglia and attenuated disease in SOD1 mice. *Annals of Neurology*. 2015;77(1):75-99.

119. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, **Cudkowitz ME**, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT, the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. *Annals of Clinical Translational Neurology*. 2016 ;3(2):132-145.
120. Weiss MD, Macklin EA, Simmons Z, Knox A, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH, Distad BJ, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, **Cudkowitz ME**. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. *Neurology*. 2016; 86(16):1471-1481.
121. Glass JD, Hertzberg VS, Boulis NM, Riley JP, Polak M, Bordeau J, Fournier CN, Johe K, Hazel T, **Cudkowitz ME**, Atassi N, Borges LF, Rutkove S, Duell J, Patil PG, Goutman SA, Feldman EL. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. *Neurology*. 2016; 87(4):392-400.
122. Shefner JM, Liu D, Leitner M, Schoenfeld D, Johns DR, Ferguson T, **Cudkowitz ME**. Quantitative Strength Testing in ALS Clinical Trials. *Neurology*. 2016; 87(6):617-624.
123. O'Reilly E, Liu D, Johns D, **Cudkowitz ME**, Paganoni S, Schwarzschild M, Leitner M, Acherios A. Serum Urate at Trial Entry and ALS Progression in EMPOWER. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2016: 18(1-2)120-125.
124. Lyden P, Weymer S, Coffey C, **Cudkowitz M**, Berg S, O'Brien S, Fisher M, Haley EC, Khatri P, Saver J, Levine S, Levy H, Rymer M, Wechsler L, Jadhav A, Waddy S, McNeil E, Pryor K. Selecting Patients for Intra-arterial Therapy in the Context of a Clinical Trial for Neuroprotection. *Stroke*. 2016; 47(12):2979-2985.
125. Roberts AL, Johnson, NJ, Chen JT, **Cudkowitz ME**, Weisskopf MG. Race/ethnicity, socioeconomic status and ALS mortality in the United States. *Neurology*. 2016; 87(22):2300-2308.
126. Fox RJ, Coffey CS, **Cudkowitz ME**, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koeppe M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flore A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeta A, on behalf of the NN102/SPRINT-MS Study. Design, Rationale, and Baseline Characteristics of the Randomized Double-Blind Phase II Clinical Trial of Ibudilast in Progressive Multiple Sclerosis. *Contemporary Clinical Trials*. 2016;50:166-177.
127. Alshikho M, Zürcher NR, Loggia ML, Cernasov P, Chonde DB, Izquierdo Garcia David, Yasek JE, Akejuc O, Catana C, Rosen BR, **Cudkowitz ME**, Hooker JM, Atassi N. Glial Activation Co-

localizes with Structural Abnormalities in Amyotrophic Lateral Sclerosis. *Neurology*. 2016; 87(24):2554-2561.

128. Fournier CN, Murphy A, Loci L, Mitsumoto H, Lomen-Hoerth C, Kisanuki Y, Simmons Z, Maragakis NJ, McVey AL, Al-Lahham T, Heiman-Patterson TD, Andrews J, McDonnell E, **Cudkowicz M**, Atassi N. Primary Lateral Sclerosis and Early Upper Motor Neuron Disease Characteristics of a Cross Sectional Population. *Journal Clinical Neuromuscular Disease*. 2016; 17(3):99-105.
129. Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, Macklin EA, Schoenfeld D, **Cudkowicz M**, Sherman A. How common are ALS plateaus and reversals? *Neurology*. 2016;86(9):808-812.
130. Roberts AL, Johnson NJ, Cudkowicz ME, Eum KD Weisskopf MG. Job-related formaldehyde exposure and ALS mortality in the USA. *J Neurol Neurosurg Psychiatry*. 2016;87(7):786-8.
131. McGarry A, McDermott M, Kiebertz K, de Blicke EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee W, Guttman M, Wojcieszek J, Kumar R, LeDoux M, Jenkins M, Rosas D, Nance M, Biglan K, Como P, Dubinsky R, Shannon K, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock V, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor S, Higgins D, Molho E, Revilla F, Caviness J, Friedman J, Perlmutter J, Feigin A, Anderson K, Rodriguez R, McFarland N, Margolis R, Farbman E, Raymond L, Suski V, Kostyk S, Colcher Am Seeberger L, Epping E, Esmail S, Diaz N, Alan Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, **Cudkowicz ME**. A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease. *Neurology*. 2017; 88(2):152-159.
132. Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, **Cudkowicz ME**, Miller T. Defining SOD1 ALS Natural History to Guide Therapeutic Clinical Trial Design. *Journal of Neurology, Neurosurgery & Psychiatry*. 2017; 88(2):99-105.
133. Smith R, Myers K, Sirdofsky M, Goslin K, Meekins G, Yu H, Wymer J, **Cudkowicz M**, Macklin EA, Schoenfeld D, Pattee G. Enhanced bulbar function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. *Neurotherapeutics*. 2017; 14(3):762-772.
134. Paganoni S, Macklin EA, Karam C, Yu H, Gonterman F, Fetterman KA, **Cudkowicz M**, Berry J, Wills AM. Vitamin D levels are associated with gross motor function in ALS. *Muscle and Nerve*. 2017; 56(4):726-731.
135. Andres PL, Allred MP, Stephens HE, Proffitt MK, Siener C, Macklin EA, Haines T, English RA, Fetterman KA, Kasarkis EJ, Florence J, Simmons Z, **Cudkowicz ME**. Fixed Dynamometry is More Sensitive than Vital Capacity or ALS Rating Scale. *Muscle and Nerve*. 2017; 56(4):710-715.

136. Paganoni S, McDonnell E, Schoenfeld D, Yu H, Deng J, Atassi H, Sherman A, Yerramilli-Rao P, **Cudkowicz M**, Atassi. Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS) *Journal Neurology Neurophysiology*. 2017; 8(2):423.
137. Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blicke EA, Auinger P, **Cudkowicz M**, Atassi N. Analysis of participant withdrawal in Huntington disease clinical trials. *Journal of Huntington's Disease*. 2017; 6(2):149-156.
138. Paganoni S, Nicholson K, Leigh F, Swoboda K, Chad D, Drake K, Haley K, **Cudkowicz M**, Berry JD. Developing Multidisciplinary Clinics for Neuromuscular Care and Research. *Muscle and Nerve*. 2017; 56(5):848-858.
139. Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, **Cudkowicz M**, Hersch S, Sampaio S, Dorsey ER, Leavitt BR, Kiebertz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ, for the TRACK-HD, COHORT, CARE-HD, and 2CARE HSG investigators. Motor, cognitive, and functional decline contribute to a single progressive factor in early HD. *Neurology*. 2017; 89(24):2495-2502.
140. Paganoni S, Alshikho MJ, Zürcher NR, Cernasov P, Babu S, Loggia ML, Chan J, Chonde DB, Garcia DI, Catana C, Mainero C, Rosen BR, **Cudkowicz ME**, Hooker JM, Atassi N. Imaging of Glia Activation in People with Primary Lateral Sclerosis. *NeuroImage: Clinical*. 2017; 17:347-353.
141. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons, J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, **Cudkowicz ME**, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT. Natural History of Infantile-Onset Spinal Muscular Atrophy. *Annals of Neurology*. 2017; 82(6):883-891. PMID: 29149772
142. Paganoni S, Nicholson K, Chan J, Shui A, Schoenfeld D, Sherman A, Berry J, **Cudkowicz M**, Atassi N for the Pooled Resource Open-Access ALS Clinical Trials Consortium. Urate Levels Predict Survival in ALS: Analysis of the Expanded PRO-ACT Database. *Muscle and Nerve*. 2018; 57(3):430-434.
143. Clawson LL, **Cudkowicz ME**, Krivickas L, Brooks BR, Sanjak M, Allred P, Atassi N, Swartz A, Steinhorn G, Uchil A, Riley K, Yu H, Schoenfeld DA, Maragakis NJ. A Randomized Controlled Trial of Resistance and Endurance Exercise in ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal*. 2018; 19(3-4):250-258. PMID: 29191052.
144. Andrews JA, **Cudkowicz ME**, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. Vitality-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal*. 2018; 19(3-4):259-266.

145. Fournier CN, Schoenfeld D, Berry JD, **Cudkowitz M**, Chan J, Quinn C, Brown R, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD. An Open Label Study of a Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal*. 2018; 19(3-4):242-249.
146. Nicolas A*, Kenna KP*, Renton AE*, Ticozzi N*, Faghri F*, Chia R*,.....**Cudkowitz M**, (73rd of 200+ authors), Stone DJ*, Tienari P*, Silani V*, Chiò A*, Shaw CE*, Traynor BJ*, Landers JE*. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron*. 2018; 97(6):1268-1283. PMID: 29566793.
147. Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau-Pazos M, Parziale N, Joyce NC, Mandeville R, Goyal N, **Cudkowitz ME**, Weiss M, Miller RG, McDonald CM. Mexiletine for Muscle Cramps in ALS: A Randomized Double-Blind Crossover Trial. *Muscle & Nerve*. 2018; 58(1):42-48.
148. Benatar M, Wu J, Anderson PM, Atassi N, William D, **Cudkowitz M**, Schoenfeld D. Randomized, Double-Blind, Placebo-Controlled Trial of Arimoclomol in Rapidly Progressive SOD1 ALS. *Neurology*. 2018; 90(7):e565-e574.
149. Lechtzin N, **Cudkowitz ME**, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA. Respiratory Measures in Amyotrophic Lateral Sclerosis. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2018; 19(5-6):321-330.
150. McCampbell A, Cole T, Wegener AJ, Giulio ST, Setnicka A, Farley BJ, Schoch KM, Hoyer ML, Shabsovich M, Sun L, Luo Y, Zhang M, Thankamony S, Salzman DW, **Cudkowitz M**, Graham DL, Bennett CF, Kordasiewicz HB, Swayze EE, Miller TM. Antisense Oligonucleotides Extend Survival and Reverse Decrement in Muscle Response in ALS Models. *The Journal of Clinical Investigation*. 2018; 128(8):3558-3567.
151. Goutman SA, Brown MB, Glass JD, Boulis NM, Johe K, Hazel T, **Cudkowitz M**, Atassi N, Borges L, Patil PG, Sakowski SA, Feldman EL. Long-term Phase ½ Intraspinal Stem Cell Transplantation Outcomes in ALS. *Annals of Clinical and Translational Neurology*. 2018;5(6):730-740.
152. Salter M, Corfield E, Ramadass A, Grand F, Green J, Westra J, Lim CR, Farrimond L, Feneberg E, Scaber J, Thompson A, Ossher L, Turner M, Talbot K, **Cudkowitz M**, Berry J, Hunter E, Akoulitchev A. Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. *EbioMedicine Journal*. 2018; 33:169-184.
153. Heiman-Patterson TD, **Cudkowitz ME**, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH. Understanding the use of NIV in ALS: results of an international ALS specialist survey. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2018; 19(5-6):331-341.

154. Thonhoff J, Beers D, Zhao W, Pleitez M, Simpson E, Berry J, **Cudkowicz M**, Appel S. Expanded Autologous Regulatory T Lymphocyte Infusions in ALS: A Phase 1, First-in-Human Study. *Neurology Neuroimmunology & Neuroinflammation Journal*. 2018; 5(4):e465.
155. Bartlett Amy, Kolb SJ, Kingsley A, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parson J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Coffey CS, Yankey JW, **Cudkowicz ME**, McGovern MM, McNeil DE, Arnold WD, Kissel JT. Recruitment & Retention Program for the NeuroNEXT SMA Biomarker study: Super Babies for SMA! *Contemporary Clinical Trials Communications*. 2018; 11:113-119.
156. Fox RJ, Coffey CS, Conwit R, **Cudkowicz ME**, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Geisser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A. A Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. *The New England Journal of Medicine*. 2018; 379(9):846-855. PMID: 30157388.
157. Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, **Cudkowicz M**, Paganoni S. Pilot Trial of Inosine to Elevate Urate Levels in Amyotrophic Lateral Sclerosis. *Annals of Clinical and Translational Neurology*. 2018; 5(12):1522-1533.
158. Paganoni S, Alshikho MJ, Luppino S, Chan J, Pothier L, Schoenfeld D, Andres PL, Babu S, Zürcher NR, Loggia ML, Barry RL, Luotti S, Nardo G, Trolese MC, Pantalone S, Bendotti C, Bonetto V, De Marchi F, Rosen B, Hooker J, **Cudkowicz M**, Atassi N. A Pilot Trial of RNS60 in Amyotrophic Lateral Sclerosis. *Muscle & Nerve*. 2019; 59(3):303-308.
159. Lyden P, Pryor KE, Coffey CS, **Cudkowicz M**, Conwit R, Jadhav A, Sawyer RN, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Healey EC, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Haacke EM, Fawaz M, Davis TP, Toga AW, Griffin JH, Zlokovic BV. Final Results of the RHAPSODY Trial. *Annals of Neurology*. 2019; 85(1):125–136.
160. McGarry A, McDermott MP, Kieburtz K, Fung WLA, McCusker E, Peng J, de Bleeck EA, **Cudkowicz M**. Risk Factors for Suicidality in Huntington’s Disease: An Analysis of the 2CARE Clinical Trial. *Neurology*. 2019; 92(14):e1643-e1651.
161. Kueffner R, Atassi N, Bronfeld M, Balagurusamy V, DiCamillo B, Chio A, **Cudkowicz ME**, Dillenberger D, Garcia-Garcia J, hardiman O, Hoff B, Knight J, Leitner ML, Li G, Mangravite L, Norman T, Wang L, Xiao J, Wen-Chieh F, Peng J, Yang C, Zach N, Norel R, Chang HJ, Stolovitzky G. Stratification of Amyotrophic Lateral Sclerosis Patients: A Crowdsourcing Approach. *Scientific Reports*. 2019; 9(1):690.

162. Goutman SA, Brown MB, **Cudkowicz M**, Atassi N, Feldman E. ALS/SURV: a modification of the CAFS statistic. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2019; 20(7-8):576-583.
163. Shefner JM, **Cudkowicz ME**, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. A Phase III Trial of Tirasemtiv as a Potential Treatment for Amyotrophic Lateral Sclerosis. *Amyotrophic Lateral Sclerosis Frontotemporal Degeneration Journal*. 2019; 20(7-8):584-594.
164. Cammack A, Atassi N, Hyman T, van den Berg LH, Harms M, Baloh RH, Brown RH, van Es MA, Veldink JH, de Vries BS, Rothstein JD, Drain C, Jockel-Balsarotti J, Malcolm A, Boodram S, Salter A, Wightman N, Yu H, Sherman AV, Esparza TJ, McKenna-Yasek D, Owegi MA, Douthwright C, McCampbell A, Ferguson T, Cruchaga C, **Cudkowicz M**, and Miller TM. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. *Neurology*. 2019; 93(17):e1605-e1617.
165. Wosiski-Kuhn M, Robinson M, Strupe J, Arounleut P, Martin M, Caress J, Cartwright M, Bowser R, **Cudkowicz M**, Langefeld C, Hawkins G, and Milligan C. IL6 Receptor 358Ala Variant and Transsignaling are Disease Modifiers in ALS. *Neurology Neuroimmunology & Neuroinflammation Journal*. 2019; 6(6):e631.
166. Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, Walker J, Simmons Z, David WS, Barkhaus PE, Simionescu L, Dimachkie MM, Pestronk A, Salameh JS, Weiss MD, Brooks BR, Schoenfeld D, Shefner J, Aggarwal S, **Cudkowicz ME**, Atassi N. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal*. 2019; 21(1-2):15-23.
167. Bedlack R, Pogemiller A, Shefner J, **Cudkowicz M** & Heiman-Patterson T. ALS clinical research learning institutes (ALS-CRLI): Empowering People with ALS to be Research Ambassadors, *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal*. 2020; 21(3-4):216-221.
168. Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, van den Berg LH, Genge A, Miller R, Baloh RH, Kern R, Gothelf Y, Lebovits C, **Cudkowicz M**. Addressing Heterogeneity in Amyotrophic Lateral Sclerosis Clinical Trials. *Muscle and Nerve*. 2019; 62(2):156-166. PMID: 31899540.
169. Berry JD, **Cudkowicz ME**, Windebank AJ, Staff NP, Owegi M, Nicholson K, McKenna-Yasek D, Levy YS, Abramov N, Kaspi H, Mehra M, Aricha R, Gothelf Y, Brown RH. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. *Neurology*. 2019; 93(24):e2294-e2305.
170. Wills AM, Garry J, Hubbard J, Mezoian T, Breen CT, Ortiz-Miller C, Nalipinski P, Sullivan S, Berry JD, **Cudkowicz M**, Paganoni S, Chan J, Macklin EA. Nutritional counseling with or without mobile health technology: a randomized open-label standard of care controlled trial in ALS. *BMC Neurology*. 2019;19(1):104.

171. **Cudkowicz M**, Chase MK, Coffey CS, Ecklund DJ, Thornell BJ, Lungu C, Mahoney K, Gutmann L, Shefner JM, Staley KJ, Bosch M, Foster E, Long JD, Bayman EO, Torner J, Yankey J, Peters R, Huff T, Conwit RA, Shinnar S, Patch D, Darras BT, Ellis A, Packer RJ, Marder KS, Chiriboga CA, Henchcliffe C, Moran JA, Nikolov B, Factor SA, Seeley C, Greenberg SM, Amato AA, DeGregorio S, Simuni T, Ward T, Kissel JT, Kolb SJ, Bartlett A, Quinn JF, Keith K, Levine SR, Gilles N, Coyle PK, Lamb J, Wolfe GI, Crumlish A, Mejico L, Iqbal MM, Bowen JD, Tongco C, Nabors LB, Bashir K, Benghe M, McDonald CM, Henricson EK, Oskarsson B, Dobkin BH, Canamar C, Glauser TA, Woo D, Molloy A, Clark P, Vollmer TL, Stein AJ, Barohn RJ, Dimachkie MM, Le Pichon JB, Benatar MG, Steele J, Wechsler L, Clemens PR, Amity C, Holloway RG, Annis C, Goldberg MP, Andersen M, Iannaccone ST, Smith AG, Singleton JR, Doudova M, Haley EC, Quigg MS, Lowenhaupt S, Malow BA, Adkins K, Clifford DB, Teshome MA, Connolly N. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. *Jama Neurology*. 2020; 77(6):755-763.
172. Miller T, **Cudkowicz M**, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA. Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *New England Journal Medicine*. 2020; 383(2):109-119. PMID: 32640130.
173. Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott M, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson K, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu, H Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, **Cudkowicz ME**. Trial of Sodium Phenylbutyrate/Taurursodiol for Amyotrophic Lateral Sclerosis. *New England Journal Medicine*. 2020; 383(10):919-930. PMID: 32877582.
174. Andrews JA, Berry JD, Baloh RH, Carberry N, **Cudkowicz ME**, Dedi B, Glass J, Maragakis NJ, Miller TM, Paganoni S, Rothstein J, Shefner JM, Simmons Z, Weiss MD, Bedlack RS. Amyotrophic Lateral Sclerosis Care and Research in the USA During the COVID-19 Pandemic: Challenges and Opportunities. *Muscle & Nerve*. 2020; 62(2):182-186. PMID: 32445195.
175. Mueller C, Berry JD, McKenna-Yasek D, Gernoux G, Owegi M, Pothier L, Douthwright C, Gelevski D, Luppino S, Blackwood M, Wightman N, Oakley DH, M.D., Frosch MP, Flotte T, **Cudkowicz ME**, Brown, Jr, RH. SOD1 Gene Expression with Adeno-associated Virus and MicroRNA in Familial ALS. *New England Journal Medicine*. 2020; 383(2):151-158.

176. Berry J, Brooks B, Genge AL, Heiman-Patterson T, Appel SH, Benatar M, Bowser R, **Cudkowicz ME**, Gooch CL, Shefner JM, Westra J, Agnese W, Merrill C, Nelson S, and Apple S. Radicava/Edaravone Findings in Biomarkers from ALS (REFINE ALS): Protocol and Study Design. *Neurology*. 2020; doi.org/10.1212/CPJ.0000000000000968.
177. Wainger BJ, Macklin EA, Vucic S, McIllduff CE, Paganoni s, Maragakis NJ, Bedlack R, MD. Goyal NA, Rutkove SB, Lange D, Rivner MH, Goutman SA, Ladha S, Mauricio E, MD, Baloh RH, Simmons Z, Pothier L, Baedorf Kassis S, La T, Hall M, Evora A, BA, Klements D, Hurtado A, Pereira JD, Koh J, Celnik P, Chaudhry V, Gable K, Juel V, Phielipp N, Marei A, Rosenquist P, Meehan S, Oskarsson B, Lewis R, Kaur D, Kiskinis E, Woolf CJ, Eggan K, Weiss MD, Berry J, David W, Davila-Perez P, Camprodon JA, Pascual-Leone A, Kiernan MC, Shefner JM, Atassi N, **Cudkowicz ME**. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. *Jama Neurology*. 2020; In-Press.
178. Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, **Cudkowicz M**, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch S, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Bengé M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang R, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, and Drazinic C. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients: A Randomized Phase 2 Clinical Trial. *Journal of Clinical Microbiology*. 2020; 9(11):3682.
179. Andronesi OC, Nicholson K, Jafari-Khouzani K, Bogner W, Wang J, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Schwarzschild MA, **Cudkowicz M**, Rosen BR, Pananoni S, and Ratai EM. Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. *Frontiers in Neurology*. 2020 doi: 10.3389/fneur.2020.590573
180. Granucci EJ, Griciuc A, Mueller KA, Mills AN, Le H, Dios AM, McGinty D, Pereira J, Elmaleh D, Berry JD, Paganoni S, **Cudkowicz ME**, Tanzi RE, Sadri-Vakili G. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1 Mouse Model of Amyotrophic Lateral Sclerosis. 2019; 9(1):17728.
181. Weiss M, Macklin E, McIllduff C, Vucic S, Wainger B, Kiernan M, Goutman S, Goyal N, Rutkove S, Ladha S, Chen I, Harms M, Brannagan T, Lacomis Dm Zivkovic S, Ma M, Wang L, Simmons Z, Hershey MS, River M, Shefner J, **Cudkowicz M**, and Atassi N. Effects of Mexiletine on Hyperexcitability in Sporadic ALS: Preliminary Findings from A Small Phase II Randomized Controlled Trial. *Muscle and Nerve*. 2020; DOI: 10.1002/mus.27146. PMID: 33340120.
182. Turner MR, Barohn RJ, Corcia P, Fink JK, Harms MB, Kiernan MC, Ravits J, Silani V, Simmons Z, Statland J, van den Berg LH: Delegates of the 2nd International PLS Conference, Mitsumoto H. Primary Lateral Sclerosis: consensus diagnostic criteria. *J Neurol Neurosurg Psychiatry*. 2020;91(4):373-77. PMID: 32029539.

183. Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson TD, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Hall M, Kittle G, Eydinov M, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, St. Pierre ME, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Yu ZF, Cohen J, Klee J, Kent L, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, **Cudkowicz ME**. Long-Term Survival of Participants in the CENTAUR Trial of Sodium Phenylbutyrate-Taurursodiol in ALS. *Muscle & Nerve*. 2021;63(1):31-39. PMID: 33063909.
184. Petrozziello T, Amaral AC, Dujardin S, Farhan SMK, Chan J, Trombetta BA, Kivisäkk P, Mills AN, Bordt EA, Kim SE, Dooley PM, Ghosal A, Gomez-Isla T, Hyman BT, Arnold SE, Spires-Jones T, **Cudkowicz ME**, Berry JD, Sadri-Vakili G. An in-depth analysis of phosphorylated tau in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. medRxiv doi: <https://doi.org/10.1101/2020.12.30.20248944>.
185. Rudnicki S, Meng L, Bian A, Wolff AA, Andrews JA, Cockroft B, **Cudkowicz M**, Hardiman O, Shefner JM, Malik FI. Non-invasive ventilation use in patients enrolled in VITALITY-ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2021; 19(3):266-267.
186. Rodriguez S, Sahin A, Schrank BR, Al-Lawati H, Constantino I, Benz E, Fard D, Albers AD, Cao L, Gomez AC, Evans, K, Ratti E, **Cudkowicz M**, Frosch MP, Talkowski M, Sorger PK, Hyman BT, Albers MW. Genome-encoded Cytoplasmic Double-Stranded RNAs, Found in C9ORF72 ALS-FTD Brain, Propagate Neuronal Loss. *Science. Translational Medicine*. 2021, In-Press.
187. Ratti E, Domoto-Reilly K, Caso C, Murphy A, Brickhouse M, Hochberg D, Makris N, **Cudkowicz ME**, Dickerson BC. Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD. *Brain Imaging and Behavior*. 2021; doi: 10.1007/s11682-021-00456-1.
188. Rudnicki SA, Andrews JA, Bian A, Cockroft BM, Cudkowicz ME, Hardiman O, Malik FI, Meng L, Wolff AA, Shefner JM. Noninvasive ventilation use by patients enrolled in VITALITY-ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2021; doi: 10.1080/21678421.2021.1904993.
189. Weiss MD, Macklin EA, McIluff CE, Vucic S, Wainger BJ, Kiernan MC, Goutman SA, Goyal NA, Rutkove SB, Ladha SS, Chen I-HA, Harms MB, Brannagan TH, Lacomis C, Zivkovic S, Ma M, Wag LH, Simmons Z, Rivner MH, Shefner JM, **Cudkowicz ME**, Atassi N. Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. *Muscle and Nerve*. 2021; 63(3):371-383.
190. Babu S, Hightower BG, Chan J, Wimmer NZ, Kivisäkk P, Tseng CEJ, Sanders DL, Robichaud A, Banno H, Evora A, Ashokkumar A, Pothier L, Paganoni S, Chew S, Dojillo J, Matsuda K, Gudesblatt M, Berry JD, **Cudkowicz ME**, Hooker JM, and Atassi N. Ibutilast (MN-166) in Amyotrophic Lateral Sclerosis- An Open Label, Safety and Pharmacodynamic Trial. *NeuroImage: Clinical*. 2021; doi: 10.1016/j.nicl.2021.102672
191. Stacy A, Rudnicki, SA, Andrews JA, Bian A, cockroft BM, **Cudkowicz ME**, Hardiman O, Malik FI, Meng L, Wolff AA, Shefner JM. Noninvasive ventilation use by patients enrolled in

VITALITY-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal. 2021; doi.org/10.1080/21678421.2021.1904993.

192. Milligan C, Atassi N, Babu S, Barohn RJ, Caress JB, **Cudkowicz ME**, Evora A, Hawkins GA, Wosiski-Kuhn M, Macklin EA, Shefner JM, Simmons Z, Bowser RP, Ladha SS. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. *Muscle and Nerve*. 2021; doi: 10.1002/mus.27339.
193. **Cudkowicz M**, Genge A, Maragakis N, Petri s, van den Berg L, Aho V, Sarapohja T, Kuoppamäki M, Garratt C, Al-Chalabi A. Oral levosimendan in participants with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled phase 3 trial. *Lancet Neurology*. 2021; In-Press.
194. Petrozziello T, Bordt EA, Mills AN, Kim SE, Sapp E, Devlin BA, Obeng-Marnu AA, Farhan SMK, Amaral AC, Dujardin S, Dooley PM, Henstridge C, Oakley DH, Neueder A, Hyman BT, Spires-Jones TL, Bilbo SD, Vakili K, **Cudkowicz ME**, Berry JD, DiFiglia M, Silva MC, Haggarty SJ, and Sadri-Vakili G. Targeting tau mitigates mitochondrial fragmentation and oxidative stress in amyotrophic lateral sclerosis. *BioRxiv*. 2021; doi: 10.1101/2021.03.22.436505.
195. Lowenhaupt S, Molloy A, Haley E, Quigg MS, Coffey C, **Cudkowicz M**, Chase M, Ecklund D. Virtual coordinator and site training and reorganization of a multisite consortium upon grant renewal: Challenges of the NeuroNEXT network. *Contemporary Clinical Trials* 2021; in-press.
196. Vucic S, Ferguson TA, Cummings C, Hotchkin MT, Genge A, Glanzman R, Roet KCD, **Cudkowicz M**, Kiernan MC. Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment. *Muscle and Nerve*. 2021; doi: [10.1002/mus.27392](https://doi.org/10.1002/mus.27392)
197. Young C, Pinto S, Grosskreutz J, Hardiman O, Clawson LL, **Cudkowicz ME**, Andrews JA. Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2021; doi: 10.1080/21678421.2021.1920981

Other peer-reviewed publications

1. **Cudkowicz ME**, Sayegh MH, Rennke HG. Membranous Nephropathy in a patient with renal cell carcinoma. *American J Kidney Diseases* 1991;XVII(3):349-351.
2. Merkel PA, Koroshetz WJ, Irizarry MC, and **Cudkowicz ME**. Cocaine-Associated Cerebral Vasculitis. *Seminars in Arthritis and Rheumatology*, 1995;25(3):172-183.
3. Blumenfeld H, Cha JC, **Cudkowicz ME**. Trimethoprim and Sulfonamide Associated Meningoencephalitis with MRI Correlates. *Neurology* 1996;46(2):556-558.
4. Vucic S, Chong PS, Dawson KT, **Cudkowicz ME** Cros D. Thromboembolic complications of intravenous immunoglobulin treatment. *European Neurology*. 2004;52(3): 141-144.
5. Schoenfeld DA, **Cudkowicz ME**. Design of phase II ALS clinical trials. *Amyotroph. lateral scler.*. 9(1):16-23, 2008.

6. Bayayan I, Cudkowicz ME. Profound muscle weakness and pain after one dose of Actonel. *Case Rep Med.* 2009;2009:693014.

Research publications without named authorship

1. Huntington Study Group*. Unified Huntington's Disease Rating Scale: Reliability and Consistency. *Movement Disorders* 1996;11(2):136-142 (*member of the investigative team cited in the appendix of the manuscript).
2. Miller RG, Anderson FA, Bradley WG, Brooks BR, Mitsumoto H, Munsat TL, Ringel SP, and the ALS CARE Study Group*. The ALS Patient Care Database. *Neurology* 2000;54:53-57 (*member of the investigative team cited in the appendix of the manuscript).
3. Bradley WG, Anderson F, Bromberg M, Gutmann, L, Harati Y, Ross M, Miller RG, and the ALS CARE Study Group*. Current management of ALS: Comparison of the ALS CARE database and the AAN practice parameter. *Neurology* 2001;57:500-504 (*member of the investigative team cited in the appendix of the manuscript).
4. The Huntington Study Group*. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. *Neurology* 2001;57:397-404 (*member of the investigative team cited in the appendix of the manuscript).
5. Paulson JS, Zhao H, Stout JC, Brinkmann RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I, and the Huntington Study Group*. Clinical markers of early disease in persons near onset of Huntington's disease. *Neurology* 2001;57:658-662 (*member of the investigative team cited in the appendix of the manuscript).
6. Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, Kayson E, Orme C, Shoulson I and the Huntington Study Group*. Predictors of nursing home placement in Huntington disease. *Neurology* 2003;60: 998-1001 (*member of the investigative team cited in the appendix of the manuscript).
7. Huntington Study Group*. Dosage Effects of Riluzole in Huntington's Disease: A Multi-Center Placebo-Controlled Study. *Neurology* 2003;61:1551-1556 (*Co-Principal Investigator, member of the investigative team cited in the appendix of the manuscript).
8. Huntington Study Group*. Minocycline Safety and Tolerability in Huntington's Disease. *Neurology* 2004;63:547-549. (*Principal Investigator; lead author)
9. Brooks BR, Thisted, RA, Appel, Bradley, WG, Olney RK, Berg, JE, Pope LE, Smith RA for the AVP-923 Study Group*. Treatment of pseudobulbar affect in ALS with dextromethorphan/quindine. A randomized trial. *Neurology* 2004;63:1364-1370 (*member of the investigative team cited in the appendix of the manuscript).
10. Kaufmann P, Thompson JLP, Levy G, et al for the QALS Study Group*. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify Phase III. *Annals of Neurology* 2009; 2:235-44

(*member of the investigative team cited in the appendix of the manuscript).

11. Buchsbaum R, Kaufmann P, Barsdorf AI, Arbing R, Montes J, Thompson JL; QALS Study Group*. Web-based data management for a phase II clinical trial in ALS. *Amyotroph Lateral Scler.* 2009;10(5-6):374-7 (*member of the investigative team cited in the appendix of the manuscript).
12. Huntington Study Group*. A randomized, placebo controlled trial of Latrepirdine in Huntington's Disease. *Archives of Neurology* 2010;67(2):154-160. (*Steering Committee Member)
13. Huntington Study Group*. A Futility Study of Minocycline in Huntington's Disease. *Movement Disorders*, 2010;25(13):2219-24. (**Cudkowicz ME** Corresponding Author)
14. Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R*; Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus Ultra low dose quinidine reduces pseudobulbar affect. *Ann Neurol.* 2010;68(5):693-702 (*member of the investigative team cited in the appendix of the manuscript).
15. Biglan KM, Dorsey ER, Evana RV, Ross CA, Hersch S, Shoulson I, Matson W, Kieburtz K, Huntington Study Group pre-2CARE Investigators. Plasma 8-hydroxy-2-deoxyguanosine levels in Huntington's Disease and Healthy Control treated with Coenzyme Q 10. *J Huntington's Disease.* 2012; 1(1):65-9.
16. Coxib and traditional NSAID Trialists (CNT) Collaboration (*member of investigative team cited in appendix of manuscript). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet.* 2013;382(9895):769-79. PMID: 23726390.

Non-peer reviewed scientific or medical publications/materials in print or other media

Proceedings of Meetings

1. **Cudkowicz ME**, Brown RH. An update on superoxide dismutase in familial amyotrophic lateral sclerosis. *Journal Neurological Sciences* 1996;139 (Suppl):10-15.
2. **Cudkowicz ME**, Zhang H, Qureshi M and Schoenfeld D. Maximum voluntary isometric contraction. *ALS and Other Motor Neuron Disorders.* 2004; 5 (Suppl 1): 84-85.
3. **Cudkowicz ME** and Shefner, JM. North East ALS Consortium. *ALS and Other Motor Neuron Disorders.* 2004; 5 (Suppl 1):126-127.
4. **Cudkowicz ME**, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG Toward more efficient clinical trials for amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2010; 11(3):259-65.
5. Bruijn L, **Cudkowicz ME**. Opportunities for improving therapy development in ALS. *Amyotroph Lateral Sclero and Frontotemporal Degeneration* 2014;15(3-4):169-73.

6. ALSUntangled Group. ALSUntangled update 1: investigator a bug (Lyme Disease) and a drug (Iplex) on behalf of people with ALS. *Amyotroph Lateral Scler.* 2009;10(4):248-50.
7. ALSUntangled Group. ALSUntangled update 2: investigating the Hickey Wellness Center. *Amyotroph Lateral Scler.* 2009;10(5-6):490-1.
8. ALSUntangled Group. ALSUntangled update 3: Investigating stem cell transplants at the Hospital San Jose Tecnologico de Monterrey. *Amyotroph Lateral Scler.* 2010;11(1-2):248-9.
9. ALSUntangled Group. ALSUntangled update 4: investigating the XCell-Center. *Amyotroph Lateral Scler.* 2010 May 3;11(3):337-8. (PMID:20443222)
10. ALSUntangled Group. ALSUntangled No. 5: investigating the Stowe/Morales ALS Protocol. *Amyotroph Lateral Scler.* 2010 Aug;11(4):414-6. (PMID:20564794)
11. ALSUntangled Group. ALSUntangled No. 6: Investigating Marty Murray's method. *Amyotroph Lateral Scler.* 2010 Oct;11(5):494-6. (PMID:20839919)
12. ALSUntangled Group. ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspiro) for ALS. *Amyotroph Lateral Scler.* 2010 Dec;11(6):571-3 (PMID:21077806)
13. ALSUntangled Group. ALSUntangled No. 8: Low dose naltrexone for ALS. *Amyotroph Lateral Scler.* 2011 Jan;12(1):76-8. Epub 2010 Dec 21. (PMID:21174518)
14. ALSUntangled Group. ALSUntangled No. 9: Blue-green algae (*Spirulina*) as a treatment for ALS. *Amyotroph Lateral Scler.* 2011 Mar;12(2):153-5 (PMID:21323493)
15. ALSUntangled Group. ALSUntangled No. 10: Luteolin and Lutimax. *Amyotroph Lateral Scler.* 2011 May;12(3):235-7 (PMID:21545238)
16. ALSUntangled Group. ALSUntangled No. 11: Nu Tech Mediworld. *Amyotroph Lateral Scler.* 2011 Jul;12(4):309-11. (PMID:21702736)
17. ALSUntangled Group. ALSUntangled 13: Bee venom. *Amyotroph Lateral Scler.* 2011 Nov;12(6):471-2 (PMID:22023191)
18. ALSUntangled Group. ALSUntangled No. 14: Mototab. *Amyotroph Lateral Scler.* 2012 Jan;13(1):161-4. (PMID:22214359)
19. ALSUntangled Group. ALSUntangled 15: coconut Oil. *Amyotroph Lateral Scler.* 2012 May;13(3):328-30. Epub 2012 Apr 3. (PMID:22471904)
20. ALSUntangled Group. ALSUntangled No. 16: cannabis. *Amyotroph Lateral Scler.* 2012 Jun;13(4):400-4. (PMID:22632446)
21. ALSUntangled Group. ALS untangled No. 17: "when ALS is lyme". *Amyotroph Lateral Scler.* 2012 Sep;13(5):487-91. Epub 2012 Aug 8. (PMID:22873562)

22. ALSUntangled Group. ALSUntangled no. 18: apoaequorin (Prevagen). Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):78-9. Epub 2012 Oct 3. (PMID:23030514)
23. ALSUntangled Group. ALSUntangled No. 19: Sodium chlorite. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):236-8. Epub 2013 Feb 19. (PMID:23421652)
24. ALSUntangled Group. ALS Untangled No. 20: the Deanna protocol. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. Epub 2013 May 2 (PMID:23638638)
25. ALSUntangled Group. ALS Untangled No. 21: Fecal transplants. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5-6):482-5. Epub 2013 Jul 22 (PMID:23870000)
26. ALSUntangled Group. ALSUntangled No. 22: Propofol. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):640-2. Epub 2013 Aug 23 (PMID:23971884)
27. ALSUntangled Group. ALSUntangled no. 23: the Rife machine and retroviruses. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):157-9. (PMID:24219300)
28. ALSUntangled Group. ALSUntangled No. 24: Vitamin D. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):318-20. Epub 2014 Apr 2 (PMID:24689759)
29. ALSUntangled Group. ALSUntangled no. 25: ursodiol. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):475-8. Epub 2014 Jun 27 (PMID:24972316)
30. ALSUntangled Group. ALSUntangled No. 27: Precision Stem Cell. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Jun;16(3-4):282-5. Epub 2015 Mar 26 (PMID:25807846)
31. ALSUntangled Group. ALSUntangled No. 28: Acupuncture. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Jun;16(3-4):286-9. Epub 2015 May 11(PMID:25960084)
32. ALSUntangled Group. ALSUntangled No. 29: MitoQ. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Sep;16(5-6):427-9. Epub 2015 Jun 19 (PMID:26090901)
33. ALSUntangled Group. ALSUntangled No. 30: Methylcobalamin. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Jul 23:1-4. (PMID:26203660)
34. ALSUntangled Group. ALSUntangled No. 31: Protandim. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Sep 28:1-3 (PMID:26414415)
35. ALS Untangled Group. ALSUntangled No. 32: Gluten-free diet. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Oct 16:1-3.(PMID:26473662)
36. ALS Untangled Group. ALSUntangled No. 63: Ketogenic Diets. Amyotroph Lateral Scler Frontotemporal Degener. 2021 14 Oct (PMID: 34645313)

Review, chapters, and editorials

1. **Cudkowitz ME**, Brown RH. CuZnSOD1-associated ALS. *Annals Neurology* 1997;42(2):273-4
2. **Cudkowitz ME**. Stroke in Women. In: Cudkowitz ME, Irizarry MC, editors. *Neurologic Disorders in Women*. Newton: Butterworth-Heinemann; 1997. p. 17-30
3. **Cudkowitz ME**, Brown RH, Smith RA. Free Radical Toxicity in Amyotrophic Lateral Sclerosis. In: Shaw CA editor. *Glutathione in the Nervous System*. Washington: Taylor and Francis 1998. p. 343-354
4. **Cudkowitz ME**, Brown RH. Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases. In: Jameson JL, editor. *Textbook of Molecular Medicine*. Totowa: Humana Press; 1998. p. 907-912.
5. **Cudkowitz ME**, Martin JB, Koroshetz WJ. The Neurology of Huntington's Disease. In: Joseph A, Young R, editors. *Movement Disorders in Neurology and Neuropsychiatry*. Cambridge: Blackwell Science; 1999. p. 147-1
6. **Cudkowitz ME**. Epidemiological methods in Neurology. In: Batchelor T, Cudkowitz ME, editors. *Principles of Neuroepidemiology*. Woburn: Butterworth-Heinemann; 2001:1-8.
7. Makris N, Papadimitriou GM, Worth AJ, Jenkins BG, Garrido L, Sorensen AG, Wedeen VJ, Tuch SD, Wu O, **Cudkowitz ME**, Caviness VS, Rosen BR, Kennedy DN. Diffusion Tensor Imaging. In: Davis, KL, Charney, D, Coyle, JT, Nemeroff, C, editors. *Neuropharmacology: The Fifth Generation of Progress*. Baltimore: Lippincott Williams and Wilkins; Chapter 27. Volume 3; 2002: 358-381.
8. **Cudkowitz ME** Quershi M, Shefner J. Measures and markers in ALS. *NeuroRx* 2004;1:273-284
9. **Cudkowitz ME**, Schoenfeld D, Williams. Improving the responsiveness of rating scales. The Challenge of stepping twice into the same river. *Neurology*. 2004;62: 1666–1667.
10. Choudry R, **Cudkowitz ME**. Clinical trials in ALS: the tenuous past and the promising future. *J Clinical Pharmacology*. 2005;45(12):1334-1344
11. Lau J, Conwit R, Miller R, **Cudkowitz M**. Therapeutic trials in amyotrophic lateral sclerosis: Past, present and future. *Amyotrophic Lateral Sclerosis*, 2nd ed *Brown, Swash and Pasinelli*, 2006 Chapter 18; p 357-363.
12. Lindhorst S, **Cudkowitz ME**. Commentary on: Meininger V et al. (2006) Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? *Nature Clinical Practice Neurology* 2006;2(7):364-365.
13. Choudry RC, Galvez-Jiminez N and **Cudkowitz ME**. Pharmacologic treatment of amyotrophic lateral sclerosis. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA. 2006 and 2007.

14. Bruijn LI and **Cudkowitz ME**. Therapeutic Targets for Amyotrophic Lateral Sclerosis: Current Treatments and Prospects for More Effective Therapies in the Future. *Expert Review of Neurotherapeutics*. 2006;6(3): 417-428
15. Bowser R, **Cudkowitz ME** Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. *Expert Rev. Mol. Diagn.* 2006;6(3):387-398
16. DiBernardo A, **Cudkowitz ME**. The Clinical Potential of Minocycline in ALS. *US Neurological Disease* 2006; 106.
17. DiBernardo A, **Cudkowitz ME**. Translating Preclinical Insights into Effective Human Trials in ALS. *Biochimica et Biophysica Acta* 2006;1762(11-12):1139-49.
18. Galpern WR, **Cudkowitz ME**. Coenzyme Q treatment of neurodegenerative diseases of aging Mitochondrion 2007; S146-153.
19. Dibernardo A, **Cudkowitz ME**. Commentary. MRS and Survival predication in ALS. *Journal Watch Neurology* 2007;9(4):30.
20. Butsch PO, **Cudkowitz ME**. Commentary. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis? *Experimental Neurology* 2007;206(1):11-15.
21. **Cudkowitz ME**, Mahadeva BX. *Neurology Podcast*; 2007; Dec 11th. Clinical, electrophysiological and pathological evidence for sensory abnormalities in ALS.
22. Bedlack RS, Traynor BJ, **Cudkowitz ME**. Emerging disease-modifying therapies for the treatment of motor neuron disease/**amyotrophic** lateral sclerosis. *Expert Opinion on Emerging Drugs* 2007;12(2): 229-52.
23. Lanka V, **Cudkowitz ME**. Therapy Development for ALS: Lessons Learned and Path Forward. *Amyotroph Lateral Scler* 2008;9(3):131-140.
24. Aggarwal S, **Cudkowitz ME**. ALS Drug Development: Reflections from the Past and a Way Forward. *Neurotherapeutics* 2008;5(4):516-527.
25. Aggarwal S, **Cudkowitz ME**. Commentary. Minocycline for ALS. *Journal Watch Neurology* 2008; 10(3):1.
26. Leigh PN, Meininger V, Bensimon G, **Cudkowitz ME**, Robberecht W. Minocycline for patients with ALS. Commentary. *Lancet Neurology* 2008; 7(2):119-120.
27. Meininger V, Shefner J, **Cudkowitz ME**. Lithium therapy in ALS. Commentary. *ALS* 2008; 9(2): 122.
28. **Cudkowitz ME**, Badayan I. Stem cell transplantation in ALS. *Journal Watch Neurology* 2008; 10(6):42-43.

29. Badayan I, **Cudkowicz ME**. Is it too soon for Mesenchymal Stem Cell trials in people with ALS? *Amyotroph Lateral Scler* 2008; 9(6):321-322.
30. Harel NY, Sorenson EJ, Miller RG, Bradley, WG, **Cudkowicz ME** Meininger V, Mitsumoto H, Moore DH, Silani V, Strong M, Swash M. What is next in ALS clinical trials? *Neurology* 2008; 70: 1365-1366.
31. Bedlack RS, Silani V, **Cudkowicz ME**. IPLEX and the Telephone Game: The difficulty in separating myth from reality on the internet. *Amyotroph Lateral Scler* 2009;10(3):182-184.
32. Bedlack RS, **Cudkowicz ME**. Clinical Trials in Progressive Neurological Diseases. In: Woodbury-Harris KM, Coull BM, editors: *Clinical Trials in the Neurosciences*. Front Neurol Neurosci. Basel, Karger, 2009; 25: 144–151.
33. Shefner JM, **Cudkowicz ME**. ALS and unproven treatments: What should patients and physicians do? *Neurology Today* 2009: September 18: 5-7
34. Lanka V, Wieland S, Barber J, **Cudkowicz ME**. Arimoclomol: A potential therapy under development for ALS. *Expert Opinion On Investigational Drugs* 2009: Dec;18(12):1907-18.
35. Swash MJ, **Cudkowicz ME**. Cerebrospinal fluid markers in amyotrophic lateral sclerosis: has the time come? *Neurology* 2010;74:949-950.
36. Choi E, **Cudkowicz ME**. *Motor Neuron Disease in Pocket Neurology*. Westover MB, Greer DM, Choi E, Awad KM. Editors. Lippincott Williams and Wilkins, 2010.
37. **Cudkowicz ME**, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kiebertz K, Shouldson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG. Toward more efficient clinical trials for amyotrophic lateral sclerosis. *Amyotroph Lateral Scler*. 2010;11(3):259-65.
38. Zinman L, **Cudkowicz ME**. Emerging targets and treatments in amyotrophic lateral sclerosis. *Lancet Neurol* 2011; 10(5): 481–90.
39. Berry J, **Cudkowicz ME**. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. *Clinical Investigation*. 2011; 1(10):1375-1389.
40. Atassi N, Schoenfeld D, **Cudkowicz ME**. Amyotrophic Lateral Sclerosis. In: Ravina B, Cumming J, McDermott M, Poole M, editors: *Clinical Trials in Neurology*. Cambridge University Press, 2012 Chapter 25: 273-283.
41. Gladman M, **Cudkowicz ME**, Zinman L. Enhancing Clinical Trials in Neurodegenerative Disorders: Lessons from ALS. *Current Opinion in Neurology* 2012;6:735-42
42. Berry J, **Cudkowicz ME**. New Considerations in the Design of Clinical Trials for ALS. *Clinical Investigation*. 2011; Vol. 1 No. 10: 1375-1389.

43. Paganoni S, Deng J, Jaffa M, **Cudkowicz ME**, Wills AM. “What does body mass index measure in amyotrophic lateral sclerosis and why should we care?” *Muscle and Nerve*. 2012;. 45(4):612.
44. Gladman M, **Cudkowicz ME**, Zinman L. Enhancing Clinical Trials in Neurodegenerative Disorders: Lessons from ALS. *Current Opinion in Neurology*. 2012; 25(6):735-42.
45. Berry JD, **Cudkowicz, ME**, Shefner JM. Predicting Success: Optimizing Phase II ALS Trials for the Transition to Phase III. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15(1-2):1-8.
46. Paganoni S, **Cudkowicz M**, Berry JD. Outcome measures in amyotrophic laterals sclerosis clinical trials. *Clinical Investigation*. 2014;4(7):605-618.
47. Hochberg L, **Cudkowicz ME**. Locked in, but not out? *Neurology*. 2014; 82:1-2.
48. Bruijn L, **Cudkowicz M**. ALS Clinical Trials Working Group. Opportunities for improving therapy development in ALS. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15(3-4):169-173
49. Ratti E, **Cudkowicz ME**, Berry JD. *Neurology. Motor Neuron Diseases*. Nabel EG, editor. *Scientific American Medicine (online)*. Hamilton (ON): Decker intellectual properties; 2014; April.
50. Berry JD, Cudkowicz ME, Shefner JM. Predicting success: optimizing phase II ALS trials for the transition to phase III. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15(1[2]):1-8.
51. Nicholson KA, **Cudkowicz ME**, Berry JD. Clinical trial designs in ALS: Does one design fit all? *Neurotherapeutics*. 2015;12(2):376-83.
52. Wainger BJ, Cudkowicz ME. Cortical hyperexcitability in ALS:C9orf72 Repeats. *Jama Neurology*. 2015;72(11):1235-6.
53. Zhu Y, Fotinos A, Mao L, Atassi N, Zhou EW, Ahmad S, Guan Y, Berry JD, **Cudkowicz ME**, Wang X. Neuroprotective agents target molecular mechanisms of disease in ALS. *Drug Discovery Today*. 2015; 20(1):65-75.
54. Cragg JJ, **Cudkowicz ME**, Weisskopf MG. The Role of Environmental Toxins in Amyotrophic Lateral Sclerosis Risk. *JAMA Neurol*. 2016;73(7):779-80.
55. Fotinos A, Yongjin Z, Mao LLJ, Atassi N, Zhou E, Ahmad S, Guan Y, Berry J, **Cudkowicz ME**, Wang X. Melatonin and other neuroprotective agents target molecular mechanisms of disease in amyotrophic lateral sclerosis. In: López-Muñoz F, Srinivasan V, de Berardis D, Álamo C, Kato T, ed. *Melatonin, Neuroprotective Agents and Antidepressant Therapy*. 1st ed. New Delhi, India: Springer India; 869-903.

56. Lin DJ, **Cudkowicz ME**, Cho TA. Opinion and Special Articles: Challenges and Opportunities in Defining Career Identity in Academic Neurology. *American Academy of Neurology* 2018;91:670-672.
57. Kiernan M, Vucic S, Talbot K, McDermott C, Hardiman O, Shefner J, Al-Chalabi A, Huynh W, **Cudkowicz M**, Talman P, van den Berg L, Dharmadasa T, Wicks P, Reilly C, and Turner M. Improving Clinical Trial Outcomes in Amyotrophic Lateral Sclerosis. *Nature Reviews Neurology*. 2020;18:1-15. PMID: 33340024.

Books

1. **Cudkowicz ME**, Irizarry MC, editors. *Neurologic Disorders in Women*. Newton: Butterworth-Heinemann; 1997.
2. Batchelor T, **Cudkowicz ME**, editors. *Principles of Neuroepidemiology*. Woburn: Butterworth-Heinemann; 2001

Professional educational materials or reports, in print or other media

1. **Cudkowicz ME**. New treatments for ALS. *ALSA_AAN Newsletter*. 2008.
2. Power B, **Cudkowicz ME**, Sherman A, Shefner J. TREAT ALS NEALS Clinical Trial Network. *Research ALS Today*:2010:6:4-5.

Narrative Report

My research and clinical activities are dedicated to the study and treatment of patients with neurodegenerative disorders, My research focus has been on developing novel treatments for Amyotrophic lateral sclerosis (ALS) and Huntington's Disease (HD). I designed and initiated several human clinical trials to evaluate therapies that have shown promise in preclinical studies. I built a neurology clinical trial unit to conduct high quality, informative and efficient clinical research studies. Helping young investigators become leaders in clinical research, working closely with lab based scientists to develop treatments and finding ways to accelerate the testing of high impact therapies in people with neurological disorders are some of my passions. I have led and am leading multisite networks to collaboratively develop new therapies and biomarkers for neurological disorders. As a co-founder and prior chair the Northeast ALS Consortium (NEALS), we have developed outcome measures, trained over 100 site staff and investigators, and tested several novel therapies in ALS. Several recent studies to date led have yielded positive phase II results (nuedexta, CK-2017357, NurOwn and mexiletine).

My research efforts also include studies risk factors for the development of ALS and biomarkers. I teach neurology residents and mentor neuromuscular and ALS research fellows. I currently have a U01 from the National Institute of Neurological Disorders and Stroke (NINDS) as the Coordination Center for NeuroNEXT. Within this network we are currently coordinating 8 national trials. NeuroNEXT is a phase 2 network designed to be efficient and enable the best ideas for neurotherapeutics to be tested in

people. Through this network we trained and mentored dozens of investigators in phase 2 trial design and several new investigators on how to lead and conduct multicenter trials. We also set up a central IRB for the network and a master contract system that greatly reduced start up time and administrative burden. Every trial involves patient advocates and each trial has enrolled ahead or on schedule. Data on natural history and outcome measures from the first completed study was instrumental to the FDA for their review and approval of the first drug for spinal muscular atrophy. Taken together, my research efforts constitute a comprehensive program to translate basic science breakthroughs into effective treatments for patients with neurological disorders.

The NEALS consortium, which I co-direct for 18 years was formed in 1995, consists of over 100 clinical sites in the United States and Canada dedicated to performing joint academic led clinical trials in ALS. All data management and clinical trial coordination for the group is performed under my direction at MGH. In conjunction with the NEALS consortium, I planned and completed over 20 multi-center clinical trials and biomarker initiatives in ALS. I am currently mentoring and on the steering committee for several new trials in ALS including phase II trials of retigabine, actemra, and the combination of tudca and sodium phenylbutrate. and a phase I study of an antisense oligonucleotide to superoxide dismutase (SOD1) in people with familial ALS. Within NEALS, we provide training and guidance to member clinical trial sites. We trained over 50 new principal investigators on how to design, lead and conduct multicenter trials. De-identified data from NEALS studies are shared in an open-source system called ProACT, which won an innovation award and has led to several publications and new insights into the disease. Similarly, all biosamples collected in our studies are shared openly. The biorepository is housed and managed at MGH and the Barrows Neurological Institute.

In 1994, along with Dr. Greenberg, I established the Neurology Clinical Research Institute (NCRI) at MGH. This institute that has approximately 95 full time staff who coordinate and perform data management for trials in several neurological disorders. I mentor and assist others clinical investigators in the Department of Neurology and throughout the United States with study trial design, funding applications, and regulatory compliance.

There is a critical need in neurology for highly trained clinical investigators who work collaboratively with basic scientists to develop new therapeutic strategies in patients. One of my passions to mentor young neurologists in clinical investigation. In collaboration with Drs. Ravina and Piantadosi, I was awarded a contract from the NINDS to create an annual one-week training course in Clinical Trial Methods for fellows and junior faculty members in Neurology (www.neurologytrials.org). This course was very successful and is now complete. I am an active participant in a similar NINDS sponsored course now led by Dr. William Meurer from the University of Michigan. I am actively involved in mentoring and teaching students at many levels, including high school students, college graduates, medical students, neurology residents, clinical fellows and junior faculty members.